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TREATING FOR TWO:
REFORMING MATERNAL
SUBSTANCE ABUSE POLICY
Katherine Drabiak†
ABSTRACT
In 2018, a nursing mother named Samantha Jones in
Pennsylvania made national headlines when her 10-day old infant
son Remington died from ingesting drugs through her breastmilk.
According to the coroner’s report, Remington died from a
combination of methadone, methamphetamine, and amphetamine
toxicity. The District Attorney charged Jones, who also had a
two-year old child, with criminal homicide. Jones was undergoing
Medication Assisted Treatment (MAT) and receiving prescribed
methadone for Opioid Use Disorder. Many swiftly voiced
opposition to the District Attorney, decrying the criminal charges
against Jones, arguing people with Opioid Use Disorder should be
offered treatment rather than face criminal charges. But Jones
was receiving treatment: Approximately one year prior to
Remington’s death, law enforcement found Jones – who was
pregnant with Remington at the time and enrolled in MAT –
passed out in her vehicle with her other child in the backseat.
During that incident, police charged Jones with endangering the
welfare of a child and driving under the influence of multiple illicit
drugs. In response, the court ordered Jones to continue MAT.
This tragedy – and similar reports – highlight a critical gap
in scholarship for treating pregnant and parenting women with
Substance Use Disorder: what happens when treatment does not
work? How should health professionals, policymakers and the law
respond to pregnant and parenting women who continue active
substance abuse despite receiving treatment?
Integrating pharmacology, addiction science, and current
clinical standards, this article examines research supporting
current federal policy that recommends MAT for pregnant and
nursing mothers. Treatment options such as MAT carry
implications for maternal impairment, recovery, informed
†

Associate Professor, College of Public Health and College of
Medicine, University of South Florida Health.
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consent, infant development, and child welfare. Addressing both
civil and criminal considerations, this article outlines potential
solutions for reforming maternal substance abuse policy. The high
stakes of treatment failure require re-envisioning what constitutes
compassionate effective treatment while using the law as a lever
of accountability to promote maternal recovery and prevent
crimes against infants and children.
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INTRODUCTION
In 2018, a nursing mother named Samantha Jones in Bucks
County, Pennsylvania made national headlines when her 10-day
old infant son, Remington, died from ingesting fatal drugs
through her breastmilk.1 According to the coroner’s report,
Remington died from a combination of methadone,
methamphetamine, and amphetamine toxicity.2 The Bucks
County District Attorney charged Jones, who also has a two-year
old child, with criminal homicide.3 Media sources reported that
Jones was undergoing Medication Assisted Treatment (MAT)
and receiving prescribed doses of methadone to treat her
addiction to opioid painkillers.4 Multiple commentators swiftly
voiced opposition to the District Attorney, decrying the criminal
charges against Jones, arguing that people with Substance Use
Disorder (SUD) should be offered treatment rather than face
criminal charges5 and asserting that Jones’ true penalty comes in

1.

Nadia Kounang, Mom Charged After Drugs In Breast Milk Killed
Baby, Prosecutors Say, CNN (Aug. 29, 2018), https://www.
cnn.com/2018/08/29/health/breastfeeding-drugs-homicide-chargesamantha-jones/index.html [https://perma.cc/J8K5-YZA9]; see
also Katherine Drabiak, Toxic Breastmilk: When Substance Abuse
Relapse Means Death for Baby, HARV. L. BILL HEALTH (Nov. 15,
2018), https://blog.petrieflom.law.harvard.edu/2018/11/15/toxicbreastmilk-when-substance-abuse-relapse-means-death-for-baby/
[https://perma.cc/J95N-ZWNY].

2.

Erin Laviola, Samantha Whitney Jones: 5 Fast Facts You Need to
Know, HEAVY (July 16, 2018), https://heavy.com/news/2018/
07/samantha-whitney-jones/ [https://perma.cc/ZX96-NFRH].

3.

Id.

4.

See Kounang, supra note 1.

5.

Melissa Jeltsen, Mother Accused of Killing Baby With Her Own
HUFFPOST
(July 19,
2018), https://www.
huffpost.com/entry/woman-charged-baby-death-drugs-breastmilk_n_5b4e4c36e4b0b15aba897538
[https://perma.cc/ZRM2RGD4].

Breastmilk,
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the form of grief and the loss of a child.6 In May 2019, Jones pled
guilty to involuntary manslaughter, admitting she transferred a
fatal combination of licit and illicit drugs to her son by
breastfeeding that caused his death.7 Deviating from sentencing
guidelines that usually prescribe up to ten years of prison time,
the presiding judge sentenced Jones to 36 months of probation
and 100 hours of community service.8
Although Jones’ defense attorney portrayed the death as a
tragic accident, Jones’s prior conduct, ongoing polysubstance
abuse while enrolled in MAT, and pattern of involvement with
law enforcement should have raised serious red flags.
Approximately one year prior to Remington’s death, law
enforcement found Jones – who was pregnant with Remington at
the time – passed out in her vehicle with her other child in the
backseat. During that incident, police charged Jones with
endangering the welfare of a child and driving under the influence
(DUI).9 At that time, Jones was similarly intoxicated under the
influence of methadone, methamphetamine, amphetamine, and
the antianxiety medication Clonazepam.10 According to media
reports, the court dropped part of the charges and sentenced
Jones to a period of house arrest with an order to continue drug
treatment.11
This case represents broader questions woven into the current
opioid crisis as it pertains to prenatal and parenting substance
abuse, illustrating the complexities of disentangling crime,
addiction, and treatment: When may, or should, the law
intervene to address the conduct of pregnant women who abuse
substances during pregnancy and breastfeeding? What
6.

Christian Menno, Mother Pleads Guilty in Breastfeeding Death of
Son, INTELLIGENCER (May 8, 2019), https://www.theintell.com/
story/news/courts/2019/05/08/mother-pleads-guilty-inbreastfeeding/5217310007/ [https://perma.cc/J4VY-LS8C].

7.

Id.

8.

See id.

9.

James O’Malley, New Britain Mom Accused of Killing Baby with
Drug-Laced Breast Milk, COURIER TIMES (July 13, 2018), https://
amp.buckscountycouriertimes.com/amp/11528146007
perma.cc/Q9F2-NLZJ].

10.

Id.

11.

Id.

315
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constitutes the safest and most effective treatment for pregnant
and nursing mothers with Opioid Use Disorder (OUD)? What is
the significance that Jones – and many other people with OUD –
continued to engage in polysubstance abuse despite receiving
MAT, or refuse treatment altogether? And lastly, who should be
held accountable for such tragic outcomes against the most
vulnerable members of society – infants and children?
Federal policy states that MAT constitutes a safe and
effective treatment for pregnant and nursing mothers with OUD
because it improves maternal and infant outcomes, warning that
detoxification treatment plans risk a high rate of relapse and
poses dangerous risks to the fetus.12 Although opioids used in
MAT cross the placenta and impact the developing infant - often
resulting in Neonatal Abstinence Syndrome (NAS) - the
American College of Obstetricians and Gynecologists maintains
that NAS constitutes an expected and treatable condition, and
the Substance Abuse and Mental Health Services Administration
(SAM
HSA) asserts there is no evidence that MAT is harmful during
pregnancy.13
Part I of this article explores the scientific evidence behind
promoting MAT for pregnant women, assesses claims of safety
and efficacy, and examines the evidence supporting the warning
against detoxification during pregnancy. Despite the current
12.

Treating Opioid Use Disorder During Pregnancy, NAT’L INST.
HEALTH: NAT’L INST. DRUG ABUSE (July 2017), https://
nida.nih.gov/publications/treating-opioid-use-disorder-duringpregnancy [https://perma.cc/W6TX-9RAF] [hereinafter NIDA
Treating Opioid Use Disorder During Pregnancy]; Stephen Patrick
& Davida Schiff, AAP Committee on Substance Use and
Prevention, A Public Health Response to Opioid Use in Pregnancy,
139 PEDIATRICS 1, 3 (2017); U.S. DEP’T HEALTH & HUMAN SERVS.:
SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., CLINICAL
GUIDANCE FOR TREATING PREGNANT AND PARENTING WOMEN WITH
OPIOID USE DISORDER AND THEIR INFANTS (2018) [hereinafter
SAMHSA Treating Pregnant and Parenting Women]; Opioid Use
and Opioid Use Disorder in Pregnancy, AM. COLL. OBSTETRICIANS
& GYNECOLOGISTS [hereinafter ACOG], https://www.acog.org/
clinical/clinical-guidance/committee-opinion/articles/2017/08/
opioid-use-and-opioid-use-disorder-in-pregnancy
[https://
perma.cc/77T4-ZN25] (last visited Mar. 13, 2022).

13.

Id.
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standard of care promoting benefits of MAT for pregnant
mothers, federal policy and medical recommendations downplay
or omit risks of medications used in MAT with potentially
significant implications for both maternal and neonatal outcomes.
Part II describes these gaps in current substance abuse
treatment policy for pregnant women and describes the viability
of alternatives including detoxification treatment. Building on
previous research examining the metrics assessing treatment
success,14 Part II also explores nuances involved in treating
patients struggling with addiction: continued substance abuse;
pregnant women who refuse or withdraw from treatment; and
specific implications of struggling with impairment as a nursing
or parenting mother.
Part III re-assesses risks and benefits to the maternal dyad,
describing neurological, psychological and physical effects from
opioid agonist medications that the pregnant and parenting
patient may experience while receiving MAT. This section also
describes the risks of prenatal opioid exposure including impact
on developmental, physical and neurological outcomes for infant
and child development. Following the maternal dyad during the
postpartum period, this section describes current guidelines
pertaining to lactation for nursing women enrolled in MAT and
how to address continued substance abuse while breastfeeding.
Part III provides recommendations for best practices to revise
current informed consent as both a clinical and legal standard
when physicians discuss treatment options for SUD and the risks
and benefits from MAT to pregnant and parenting women.
This article highlights a critical gap in current law and policy:
pregnant and parenting women may refuse treatment, may
discontinue treatment, may enroll in treatment but still engage
in ongoing substance abuse, or may face impairment from
medications prescribed in MAT. Both continued substance abuse
and impairment directly affects the health of the fetus, the safety
of the infant, and the mother’s ability to parent. Part IV explores
how the law classifies prenatal and parenting substance abuse,
explains the civil law system relating to child welfare laws,
describes how some states have tried to facilitate treatment
through civil commitment, and describes the intersection between
substance abuse and crimes against infants and children. This
14.

See generally Katherine Drabiak, Expanding Medication Assisted
Treatment is Not the Answer: Flaws in the Substance Abuse
Treatment Paradigm, 21 J. HEALTH CARE L. 1 (2019).
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section will also analyze the variation in how jurisdictions
approach prenatal and parenting substance abuse when it results
in the delivery of controlled substances to an infant or when the
mother causes the infant’s death.
Finally, Part V concludes by providing policy
recommendations designed to facilitate treatment, motivate
engagement and recovery, and sets forth guidelines for using the
law as an appropriate lever to deter and sanction criminal acts
against children.

I.

THE STANDARD OF CARE FOR TREATING PREGNANT
PATIENTS WITH OUD

This section will explain the pharmacology of the two opioid
agonists used in MAT (methadone and buprenorphine), possible
side effects and risks listed in FDA labeling, legal classification
under the Controlled Substances Act, and FDA labeling
information pertaining to use of methadone and buprenorphine
during pregnancy and lactation. SAMHSA and current medical
literature explicitly warn against detoxification, asserting that
supervised withdrawal is not recommended because it poses risks
to the fetus. While federal policy acknowledges that prenatal
exposure to opioids increases the risk of Neonatal Abstinence
Syndrome, SAMHSA and ACOG deny that MAT increases other
physical or neurological risks to the developing fetus or infant.
A.

Medication Assisted Treatment Constitutes the Standard of
Care for Pregnant Patients

According to the National Survey on Drug Use and Health,
about 4.4% of pregnant women report illicit drug use during
pregnancy.15 From 2004 to 2014, as more pregnant mothers
became dependent and addicted to opioids, the rates of NAS
increased five-fold, resulting in 32,000 infants born in 2014 who
suffered from NAS and opioid withdrawal.16 Professional

15.

Marylou Behnke & Vincent Smith, Committee on Substance Abuse
and Committee on Fetus and Newborn, Prenatal Substance Abuse:
Short- and Long-Term Effects on the Exposed Fetus, 131
PEDIATRICS e1009, e1010 (2013).

16.

Dramatic Increases in Maternal Opioid Use and Neonatal
Abstinence Syndrome, NAT’L INST. HEALTH: NAT’L INST. DRUG
ABUSE

(Jan.

2019),

https://archives.drugabuse.gov/trends-
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guidelines and medical recommendations warn against abrupt
discontinuation of opioids during pregnancy, stating that it can
cause preterm birth, fetal distress, and fetal demise.17 The
American College of Obstetricians and Gynecologists (ACOG)
extends the recommendation further, asserting that withdrawal
from opioids is not safe and not medically recommended.18 Instead
of withdrawal or detoxification based treatment, the American
Academy of Pediatrics (AAP), the National Institute on Drug
Abuse (NIDA), ACOG, and SAMHSA all recommend MAT as
the standard of care.19
Treating substance abuse, or assisting a pregnant patient to
discontinue substance abuse, does provide significant health
benefits for both the patient and developing infant. Pregnant
patients with untreated addiction face higher rates of infectious
disease and are at six times the risk for pregnancy complications,
and infants born to mothers with untreated addiction have lower
birth weights, higher risk of NAS, and a 74-fold increased risk of
Sudden Infant Death Syndrome.20 Pregnant patients engaged in
MAT are more likely than untreated patients to obtain prenatal
care and are less likely to experience fluctuations in opioid
exposure levels.21 The infants of patients in MAT have a higher
statistics/dramatic-increases-in-maternal-opioid-use-neonatalabstinence-syndrome [https://perma.cc/NBM3-PE8L].
17.

Patrick & Schiff, supra note 12; ACOG, supra note 12; DARLA
BISHOP ET AL., JACOB’S INST. WOMEN’S HEALTH AT GEO. WASH.
UNIV., PREGNANT WOMEN AND SUBSTANCE ABUSE: OVERVIEW OF
RESEARCH & POLICY IN THE UNITED STATES 31 (2017).

18.

ACOG, supra note 12.

19.

Patrick & Schiff, supra note 12, at 3, 5; ACOG, supra note 12;
SAMHSA Treating Pregnant and Parenting Women, supra note
12, at 25; NIDA Treating Opioid Use Disorder During Pregnancy,
supra note 12; U.S. DEP’T OF HEALTH & HUM. SERVS.: SUBSTANCE
ABUSE MENTAL HEALTH ADMIN. & ADMIN FOR CHILD. & FAMILIES,
A COLLABORATIVE APPROACH TO THE TREATMENT OF PREGNANT
WOMEN WITH OPIOID USE DISORDERS: PRACTICE AND POLICY
CONSIDERATIONS FOR CHILD WELFARE, COLLABORATING MEDICAL,
AND
SERVICE PROVIDERS (2016) [hereinafter SAMHSA
Collaborative Approach].

20.

ACOG, supra note 12; Silvia Minozzi et al., Maintenance Agonist
Treatments for Opiate-Dependent Pregnant Women, 12 COCHRANE
DATABASE SYSTEMIC REV. 2013, at 2, 7.

21.

U.S. DEP’T HEALTH & HUM. SERVS.: SUBSTANCE ABUSE MENTAL
HEALTH ADMIN., MEDICATION-ASSISTED TREATMENT FOR OPIOID
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birth weight and longer gestational age as compared to untreated
pregnancies.22
Federal policy asserts there is “consensus”23 in the medical
community that MAT plays a critical role in the treatment of
persons with opioid use disorder and that it constitutes the most
effective form of treatment.24 General guidelines set forth by
NIDA state that medication in conjunction with behavioral
therapy constitutes the most effective treatment for opioid use
disorder.25 The Office of National Drug Control Policy asserts
that medication does not merely assist with psychosocial services,
but itself constitutes a central component of evidence-based
practice.26
Professional recommendations and guidelines promoting
MAT as the standard for care also apply to pregnant patients
with OUD. AAP states that medications used in MAT,
methadone and buprenorphine, are safe and effective in
pregnancy and lead to improved maternal and infant outcomes.27
Similarly, guidelines set forth by the American Society of
ADDICTION IN OPIOID TREATMENT PROGRAMS: A TREATMENT
IMPROVEMENT PROTOCOL (TIP) 43 (2005) [hereinafter “SAMHSA
TIP 43”]; Gabrielle Welle-Strand et al., Neonatal Outcomes

Following In Utero Exposure to Methadone or Buprenorphine: A
National Cohort Study of Opioid-Agonist Treatment of Pregnant
Women in Norway from 1996-2009, 127 DRUG ALCOHOL
DEPENDENCE 200, 201 (2013).
22.

SAMHSA TIP 43, supra note 21; Welle-Strand et al., supra note
21.

23.

COMM. ON ENERGY & COM. DEMOCRATIC STAFF, 113TH CONG.,
HEARING ON “COMBATTING THE OPIOID ABUSE EPIDEMIC:
PROFESSIONAL AND ACADEMIC PERSPECTIVES” 4 (2015).

24.

NAT’L INST. HEALTH: NAT’L INST. DRUG ABUSE, MEDICATIONS TO
TREAT OPIOID USE DISORDER RESEARCH REPORT (2021)
[hereinafter MEDICATIONS TO TREAT OPIOID USE DISORDER]; NAT’L
INST. HEALTH: NAT’L INST. DRUG ABUSE, EFFECTIVE TREATMENT
FOR OPIOID ADDICTION (2016).

25.

NAT’L INST. HEALTH: NAT’L INST. DRUG ABUSE, DRUGS,
AND BEHAVIOR: THE SCIENCE OF ADDICTION (2014).

26.

Memorandum from Michael P. Botticelli, Director of the Office of
National Drug Control Policy, to Heads of Executive Departments
and Agencies, on Changing Federal Terminology Regarding
Substance Use and Substance Use Disorders (Jan. 9, 2017) (on file
at whitehouse.gov) [hereinafter ONDCP Memo].

27.

Patrick & Schiff, supra note 12.

320

BRAINS,

Health Matrix·Volume 32·2022
Treating for Two

Addiction Medicine (ASAM) and SAMHSA state that pregnant
patients with OUD should be encouraged to start on methadone
(a full opioid agonist) or buprenorphine (a partial opioid
agonist).28
B.

Pharmacology and Product Labeling Information for
Methadone and Buprenorphine
1.

Methadone

Methadone is a synthetic full opioid agonist, which binds to
and activates the same opioid receptors as heroin, morphine, and
opioid pain medications.29 It is designed for a slower and more
controlled release to prevent cravings and withdrawal symptoms
over a longer time duration.30 NIDA maintains the message that
methadone does not produce euphoria at therapeutic doses,
patients receiving methadone do not appear “high” based on their
tolerance to the drug’s effects, and patients are able to function
normally enough to attend school or work and engage in activities
of daily life.31 Under the Controlled Substances Act, methadone
is a Class II controlled substance, which means despite an
accepted medical use, it has a high potential for abuse and may
lead to severe psychological or physical dependence.32 The FDA
approved package insert for Methadose, the oral liquid used by
Opioid Treatment Providers, states that methadone can be
abused in a manner similar to other opioid agonists and are
28.

SAMHSA Collaborative Approach, supra note 19, at 10; see also
Drabiak, supra note 14, at 37-41 (describing the regulatory and
legal classification of methadone and buprenorphine and
pharmacological properties).

29.

MEDICATIONS TO TREAT OPIOID USE DISORDER, supra note 24;
MALLINCKRODT PHARM., METHADOSE ORAL CONCENTRATE 3 (2016)
[hereinafter METHADOSE].

30.

See Methadone, Medication Assisted Treatment, U.S. DEP’T
HEALTH & HUM. SERVS.: SUBSTANCE ABUSE MENTAL HEALTH
ADMIN., https://www.samhsa.gov/medication-assisted-treatment/
medications-counseling-related-conditions/methadone
[https://
perma.cc/8L3D-75XR] [hereinafter “SAMHSA Methadone”] (last
visited Mar. 12, 2022).

31.

MEDICATIONS TO TREAT OPIOID USE DISORDER, supra note 24; see

also SAMHSA Methadone supra note 30.
32.

Controlled Substances Act, 21 U.S.C. § 812(b)(2) (1971); DRUG
ENFORCEMENT ADMIN.: DIVERSION CONTROL DIV., METHADONE
(2014).
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“sought by drug abusers, people with addiction disorders . . . and
[is] subject to diversion.”33
Use of methadone carries a variety of side effects and risk of
adverse events. Side effects may include dizziness, sedation,
nausea, vomiting, sweating, confusion, agitation, dysphoria, and
insomnia.34 Risks also include life threatening QT prolongation (a
heart arrhythmia) and, similar to other opioid analgesics,
administration of methadone even in the prescribed amount can
cause respiratory depression and death.35
Methadone has unique pharmacological properties that
require cautious administration and physician oversight. The
analgesic effect of methadone lasts about 4 to 8 hours, but it
remains in the body for 8 to 59 hours, binding to tissues including
the brain.36 In risk management materials, SAMHSA has warned
that the combination of methadone’s long half-life and slow
elimination can result in the fatal accumulation of methadone in
patients, leading to iatrogenic overdose.37 Methadone also may
exert neurotoxic effects, reduce gastrointestinal motility leading
to constipation, suppress the immune system, and impact the
endocrine system.38 This may manifest as insulin imbalances,
impotence, erectile dysfunction, amenorrhea, or infertility.39 The
33.

METHADOSE, supra note 29, at 10; see also Drabiak, supra note 14,
at 37-41.

34.

METHADOSE, supra note 29, at 25.

35.

Id. at 3-4; see also AnGee Baldini et al., A Review of Potential
Adverse Effects of Long Term Opioid Therapy: A Practitioner’s
Guide, 14 PRIMARY CARE COMPANION CNS DISORDERS 3 (2010)
(discussing the long-term adverse effects of opioids as a class of
medications when used in clinical care, with mention of
constipation, sleep-disordered breathing, hypothalamic-pituitaryadrenal dysfunction, and overdose, finding a significant decline in
patients’ health related quality of life).

36.

ROXANE LAB’YS, INC., DOLOPHINE HYDROCHLORIDE CII
(METHADONE HYDROCHLORIDE TABLETS, USP) 5MG, 10MG RX
ONLY 3, 15 (2006); METHADOSE, supra note 29, at 5.

37.

Id. at 28; U.S. DEP’T HEALTH & HUM. SERVS.: SUBSTANCE ABUSE
MENTAL HEALTH SERVS. ADMIN., MINIMIZE LIABILITY, MANAGE
RISK, ENSURE PATIENT SAFETY: EFFECTIVE STRATEGIES IN
OUTPATIENT METHADONE TREATMENT WEBINAR
(2009)
[hereinafter “SAMHSA Minimize Liability”].

38.

METHADOSE, supra note 29, at 4.

39.

Id.
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FDA-approved product information for Methadose also provides
a warning statement that methadone may impair the patient’s
ability to drive or operate heavy machinery.40
Despite the profile of risks and adverse events, health
professionals maintain “essential questions of safety and efficacy
have been definitively answered” and methadone offers a safe and
effective treatment for persons with addiction because it
normalizes patient function with minimal psychoactive
impairment.41
2.

Buprenorphine

Buprenorphine is a partial opioid agonist: it binds to the
same receptors as other opioids but activates them less strongly.42
It is also designed to reduce cravings and withdrawal at
therapeutic doses, and normalize body functions without
negative and euphoric effects.43 Some formulations of
buprenorphine combine buprenorphine with naloxone, an opioid
antagonist, to function as an abuse deterrent.44 As a partial
agonist, it is designed to block the high from additional opiates;
because of this, the National Drug Intelligence Center asserts that
buprenorphine carries a lower risk of abuse or diversion based on
its “ceiling effect.”45 SAMHSA states that buprenorphine assists

40.

Id. at 13.

41.

Vincent Dole, Editorial, What Have We Learned from Three
Decades of Methadone Maintenance Treatment?, 13 DRUG &
ALCOHOL REV. 3, 3 (1994); Herbert Kleber, Methadone
Maintenance Four Decades Later: Thousands of Lives Saved, But
Still Controversial, 300 JAMA 2302, 2302 (2008).

42.

MEDICATIONS TO TREAT OPIOID USE DISORDER, supra note 24;
RECKITT BENKISER PHARM. INC., SUBUTEX 5 (2010) [hereinafter
SUBUTEX].

43.

MEDICATIONS TO TREAT OPIOID USE DISORDER, supra note 24, at
5, 12; Medication-Assisted Treatment (MAT), SUBSTANCE ABUSE
& MENTAL HEALTH ADMIN., https://www.samhsa.gov/medicationassisted-treatment [https://perma.cc/S6NR-RLQT] (last visited
Mar. 21, 2022) (hereinafter SAMHSA MAT).

44.

Id.

45.

Intelligence Bulletin: Buprenorphine: Potential for Abuse, NAT’L
DRUG INTEL. CTR. (Sept. 2004), https://www.justice.gov/
archive/ndic/pubs10/10123/index.htm [https://perma.cc/YQ2VG9Q6].
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persons with opioid abuse disorder to regain normal, healthy lives,
and permits patients to function normally.46
Under the Controlled Substances Act, buprenorphine is a
Class III controlled substance, which means the DEA has
determined it has less potential for abuse than a Class II
substance, such as methadone.47 Buprenorphine has an accepted
medical use, and abuse of it “may lead to moderate or low
physical dependence or high psychological dependence.”48
Side effects from buprenorphine include headache, nausea,
vomiting, sweating, constipation, withdrawal symptoms, anxiety,
depression, and insomnia.49 Additional adverse risks include
hepatic events, respiratory depression, and overdose, which is
more likely to occur if a patient combines buprenorphine with
central nervous system depressants such as alcohol or
benzodiazepines.50 The FDA-approved product information for
one formulation, Subutex, carries specific warnings of its potential
for dependence and abuse along with a warning Subutex may
impair the patient’s ability to drive or operate machinery.51
3.

Methadone and Buprenorphine During Pregnancy and
Lactation

In 2014, the FDA revised its rule governing the content and
format of medication labels pertaining to use during pregnancy
and lactation.52 This rule removed previous risk categories from
drug and product information and requires manufacturers to
provide specific subsections for product information and potential

46.

SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., THE FACTS
ABOUT BUPRENORPHINE FOR TREATMENT OF OPIOID ADDICTION 23, 9, 11 (2014).

47.

21 U.S.C. § 812(b)(3); Buprenorphine, DRUG ENF’T ADMIN. (July
2013), http://www.deadiversiontest.usdoj.gov/drug_chem_info/
buprenorphine.pdf [https://perma.cc/3W5A-PE8G].

48.

Controlled Substance Schedules, DRUG ENF’T ADMIN.: DIVERSION
CONTROL DIV., https://www.deadiversion.usdoj.gov/schedules/
[https://perma.cc/Q4PH-HQCS] (last visited Feb. 12, 2022).

49.

SUBUTEX, supra note 42, at 10-11.

50.

Id. at 6-8.

51.

Id. at 8.

52.

21 C.F.R. § 201 (2014).
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risks during pregnancy and lactation.53 The FDA hoped this
would assist providers in making prescribing decisions and more
adequately counsel women on the risks of specific medications.54
The FDA-approved product information states that
methadone should only be used for women in pregnancy when the
benefit to the mother outweighs the risk to the fetus of untreated
drug addiction and a potential relapse to drugs, and warns that
there are no controlled studies of methadone use in pregnant
women to establish safety.55 According to the product
information, untreated addiction often results in continued or
relapsing illicit opioid use.56 Small scale studies comparing infants
born to mothers who received methadone found decreased fetal
growth with reduced birth weight, length, and head circumference
compared to healthy controls.57 Animal data referenced in the
FDA product information describes an increased risk of neural
tube defects, increased neonatal mortality, and differences in
neurological development, learning, and behavior.58 Maternal use
of methadone can cause NAS, which can be fatal if not recognized
and treated.59 The FDA product information provides a lactation
warning that maternal use of methadone will transfer to
breastmilk in low levels during lactation, which may cause
methadone toxicity in infants; symptoms of methadone toxicity
include increased sleepiness, difficulty breastfeeding, breathing
difficulties, or limpness.60
The FDA-approved product information for buprenorphine
states that data on use in pregnancy are limited because clinical
trials studying women taking buprenorphine were not designed to
assess the risk of major malformations during pregnancy.61
Although current data does not appear to indicate an increased
risk of major malformations, some observational studies have
53.

Id.

54.

Id.

55.

METHADOSE, supra note 29, at 10, 20.

56.

Id. at 30.

57.

Id. at 21.

58.

Id. at 21-22.

59.

Id. at 10.

60.

Id. at 16, 23.

61.

SUBUTEX, supra note 42, at 14.
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reported on congenital malformations among buprenorphine
exposed pregnancies.62 In animal models, reproductive and
developmental studies identified adverse events, including an
increased risk of fetal demise, dystocia (abnormal fetal growth),
and skeletal abnormalities.63 Based on animal data, the
buprenorphine labeling instructs providers to advise pregnant
women on potential risks to the fetus.64 Similar to the FDA
product information for methadone, the label for buprenorphine
frames the risk assessment as comparing the risk of buprenorphine
to the fetus versus the risk of untreated addiction.65 Maternal use
of buprenorphine can also cause NAS, which can be fatal if not
recognized and treated.66 Like methadone, maternal use of
buprenorphine also transfers low levels of buprenorphine in
breastmilk, and lactating mothers should monitor the infant for
increased drowsiness and breathing difficulties.67
C.

Federal Policy Supporting MAT

According to SAMHSA, MAT prevents withdrawal, reduces
the patient’s cravings for illicit substances, and enables the
patient to focus on recovery.68 “SAMHSA recommends [that]
patients should use medications as long as [they] provide[] [a]
benefit.”69 SAMHSA cautions that “patients who discontinue
medication generally return to illicit opioid use” and, because of
62.

Id. at 14-15.

63.

Id. at 16.

64.

Id. at 14.

65.

Id. at 14-15.

66.

Id. at 7.

67.

Id. at 17.

68.

See SAMHSA Collaborative Approach, supra note 19; see
also Kelley Saia et al., Caring for Pregnant Women With Opioid
Use Disorder in the USA: Expanding and Improving Treatment, 5
CURRENT OBSTETRICS GYNECOLOGY REP. 257, 258 (2016) (stating
that MAT provides “an opioid blockade” and prevents euphoria
from illicit use, when
methadone
and
buprenorphine
are
opioid agonists, classified under the Controlled Substances Act an
d by the FDA as capable of producing euphoria and the DEA states
they are abused to produce euphoria.); Drabiak, supra note 14, at
37-42 (discussing the regulatory, legal, and pharmacological 1
classifications of methadone and buprenorphine).

69.

Drabiak, supra note 14, at 44.
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that possible lapse, “healthcare policy should prioritize patient
access, utilization, and expansion of MAT.”70
NIDA, SAMHSA, and the Office of National Drug Control
Policy71 have each issued specific statements asserting that it is a
“misconception” that MAT substitutes one substance use
disorder for another, lamenting that this perspective has hindered
the adoption of evidence-based treatments.72 SAMHSA maintains
its claim that patients using replacement opioids as part of MAT
receive a safe and controlled level of medication.73 NIDA asserts
that patients receiving replacement opioid agonists do not
experience euphoria because they have developed a tolerance.74
In a 2016 report, the Government Accountability Office
stated that abstinence-based treatment often fails and is less
effective than MAT.75 It argued that hesitation or opposition to
MAT indicates a “lack of understanding” of addiction and
inaccurate beliefs.76 According to ACOG, detoxification-based
treatment constitutes an inferior option and the current standard
of care prescribing MAT for patients with OUD should not be
modified based on the patient’s pregnancy status.77
D.

Standard of Care Warns Against Medically Supervised
Withdrawal

Current medical literature explicitly warns against medically
supervised detoxification treatment. Both pediatric and addiction
medicine articles argue that withdrawal increases the risk of

70.

Id.

71.

MEDICATIONS TO TREAT OPIOID USE DISORDER, supra note 24;
Medication Assisted Treatment, SUBSTANCE ABUSE & MENTAL
HEALTH ADMIN. (Jan. 10, 2022), https://www.samhsa.gov/
medication-assisted-treatment [https://perma.cc/G5KX-SYCW]
(hereafter
SAMHSA
Medication
Assisted
Treatment);
ONDCP Memo, supra note 26.

72.

SAMHSA Medication Assisted Treatment, supra note 71.

73.

Id.

74.

MEDICATIONS

75.

GOV. ACCOUNTABILITY OFFICE, OPIOID ADDITION: LAWS,
REGULATIONS, AND OTHER FACTORS CAN AFFECT MEDICATIONASSISTED TREATMENT ACCESS (2016).

76.

Id.

77.

ACOG, supra note 12.

TO

TREAT OPIOID USE DISORDER, supra note 24.
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relapse and results in the poor engagement in treatment.78
Meanwhile, it does not improve newborn health.79 Based on high
rates of return to substance abuse,80 SAMHSA states that health
care providers should encourage patients to use a combination of
pharmacotherapy and behavioral strategies in treatment and
explicitly states providers should discourage opioid withdrawal.81
In provider education materials, SAMHSA bolds the statement:
“Medically supervised withdrawal is NOT recommended.”82
SAMHSA also informs providers that abstinence is not the goal
of treatment and that discontinuation may not be feasible or
safe.83 Instead, SAMHSA aims to educate health care providers
on how to use the informed consent process as a means to convey
to the patient that pharmacotherapy will help her avoid
withdrawal, regain control of her life, and stop substance abuse.84
E.

Risk of Neonatal Abstinence Syndrome and Risks to
Developing Infant

Though federal policy recognizes that MAT provides benefit
to pregnant patients, it also acknowledges risk of NAS to the
infant. Approximately 55-94% of infants who were prenatally
exposed to opioids, whether illicit or prescribed through MAT,
will develop withdrawal symptoms from the opioid following
birth; this is referred to as Neonatal Abstinence Syndrome, or

78.

Patrick & Schiff, supra note 12; BISHOP ET AL., supra note 17; Saia
et al., supra note 68; Stacey Klaman et al., Treating Women Who

Are Pregnant or Parenting for Opioid Use Disorder and the
Concurrent Care of their Infants and Children: Literature Review
to Support National Guidance, 11 J. ADDICTION MED. 178, 181-82
(2017); HENDRÉE E. JONES, TREATING WOMEN FOR OPIOID USE
DISORDER DURING PREGNANCY: CLINICAL CHALLENGES (2019).
79.

JONES, supra note 78. See also Patrick & Schiff, supra note 12;
BISHOP ET AL., supra note 17; Saia et al., supra note 69; Klaman et
al., supra note 78, at 187.

80.

Klaman et al., supra note 79, at 181; BISHOP ET AL., supra note 17.

81.

SAMHSA Treating Pregnant and Parenting Women, supra note
12.

82.

Id.

83.

Id.

84.

Id.
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“NAS.”85 NAS refers to gastrointestinal, autonomic, and
neurological features, presenting as a constellation of symptoms
that can include excessive crying, irritability, significant weight
loss, seizures, projectile vomiting, and tremors.86 Clinical onset of
symptoms typically begins in the first few days after birth.87 But
in some instances, depending on the amount and type of
substances used by the pregnant patient, onset could begin postdischarge from the hospital.88 Testing the infant can be important
to ensure optimal care in cases where there is inadequate
information on the amount or severity of prenatal substance
exposure.89 Infants with NAS are at increased risk for admission
to the neonatal intensive care unit and birth complications.90
Additionally, they may require pharmacologic treatment and a
longer hospital stay.91
Using medical recommendations, ACOG and ASAM counsel
physicians to prescribe medication to the pregnant patient
without hesitation about whether the medication will increase the
risk or severity of NAS in the future infant.92 ACOG informs
physicians that NAS is an expected and treatable condition, and
the overwhelming scientific consensus shows that NAS does not
constitute a long-term condition.93 Although methadone and
buprenorphine readily cross the placenta,94 SAMHSA asserts that
health care providers should reassure pregnant patients that
“there is no evidence” that pharmacotherapy for MAT is harmful
to the developing infant and there is no research to indicate MAT

85.

Karen McQueen & Jodie Murphy-Oikonen, Neonatal Abstinence
Syndrome, 375 NEW ENG. J. MED. 2468, 2469 (2016).

86.

Id. at 2469-70.

87.

Id.

88.

Id.

89.

Patrick & Schiff, supra note 12.

90.

McQueen & Murphy-Oikonen, supra note 85, at 2470.

91.

Id.

92.

ACOG, supra note 12; SAMHSA Treating Pregnant and Parenting
Women, supra note 12.

93.

ACOG, supra note 12; Saia et al., supra note at 68; SAMHSA
Treating Pregnant and Parenting Women, supra note 12.

94.

Behnke & Smith, supra note 15, at e1012.
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increases risk of birth defects.95 ACOG warns that any concerns
that pharmacotherapy could result in adverse developmental
outcomes on the future infant are non-scientific and
stigmatizing.96

II.

CRITICAL ANALYSIS OF THE EVIDENCE SUPPORTING
MAT FOR PREGNANT PATIENTS

Despite federal policy and current clinical recommendations
against detoxification, research shows that supervised
detoxification is not only safe for the fetus, but can promote high
rates of successful recovery.97 Federal policy and medical
literature touting the efficacy of MAT downplay critical metrics,
such as high rates of continued opioid abuse, ongoing
polysubstance abuse, and dependence or addiction to the
prescribed medication.98 While MAT may assist some patients
with recovery and constitute a helpful tool as part of a greater
treatment plan, some patients enrolled in MAT may struggle with
impairment and conducting activities of daily life.99
A. Scientific Evidence Does Not Support the Proposition that
Medically Supervised Detoxification Poses Risks to the Pregnancy

Despite ACOG’s warning that withdrawal from opioids
during pregnancy is extremely dangerous for the fetus, ACOG
acknowledges this standard is based on limited information.100
One report noted a correlation between increased epinephrine and
norepinephrine levels in the amniotic fluid as the patient tapered

95.

SAMHSA Treating Pregnant and Parenting Women, supra note
12.

96.

ACOG, supra note 12.

97.

Steve Caritis & Ashok Panigrahy, Opioids Affect the Fetal Brain:
Reframing the Detoxification Debate, 221 AM. J. OBSTETRICS &
GYNECOLOGY 602, 602-03 (2019).

98.

Tracey L. Kelley, Pitfalls of Medication-Assisted Treatment,
WILLINGWAY (Nov. 20, 2019), https://willingway.com/pitfallsmedication-assisted-treatment/#:~:text=While%20some%20
people%20experience%20effective,or%20die%20on%20MAT%20pr
ograms [https://perma.cc/K4FL-X8ZQ].

99.

Drabiak, supra note 14, at 51-52.

100. ACOG, supra note 12.
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from medication.101 This finding suggested that withdrawal
produced fetal stress.102 A second article described a pregnant
patient with heroin addiction who was enrolled in MAT and
receiving methadone, but who continued to abuse heroin.103 The
night prior to delivery, the pregnant patient injected heroin and,
the following day, the infant was stillborn.104
Several articles in the American Journal of Obstetrics and
Gynecology, Obstetrics and Gynecology, and The Journal of
Substance Abuse Treatment have questioned whether these two
sources of narrowly limited patient reports should constitute
sufficient evidence to support a standard of care warning of severe
dangers associated with detoxification.105 Multiple other studies
conducted since the case reports in the 1970s, totaling hundreds
of patients surveyed, demonstrate the opposite: there is no clear
evidence to support that medically assisted detoxification during
pregnancy increases adverse outcomes, such as miscarriage,
premature labor, or fetal demise.106
Addiction specialist Jason Luty and colleagues conducted a
retrospective analysis of 101 pregnant patients who underwent inpatient methadone detoxification and found no evidence that
detoxification was associated with risk of miscarriage in the
101. Winston Campbell, Opioid Detoxification During Pregnancy: The
Door Continues to Open, 215 AM. J. OBSTETRICS & GYNECOLOGY
258, 258 (2016).
102. Jennifer Bell et al., Detoxification from Opiate Drugs During
Pregnancy, 215 AM. J. OBSTETRICS & GYNECOLOGY 374.e1, 374.e1
(2016); Frederick Zuspan et al., Fetal Stress from Methadone
Withdrawal, 122(1) AM J. OF OBSTETRICS AND GYNECOLOGY 43
(1975); Jose Luis Rementeria & Nemesio Nuang, Narcotic
Withdrawal in Pregnancy: Stillbirth Incidence with a Case Report,
116(8) AM J. OF OBSTETRICS AND GYNECOLOGY 1152 (1973).
103. Campbell, supra note 101.
104. Id.
105. See Bell et al., supra note 102; Campbell, supra note 101; see also
Jodi S. Dashe et al., Opioid Detoxification in Pregnancy, 92
OBSTETRICS & GYNECOLOGY 854, 854 (1998).
106. Bell et al., supra note 102; Dashe et al., supra note 105; Robert D.
Stewart et al., The Obstetrical and Neonatal Impact of Maternal
Opioid Detoxification in Pregnancy, 209 AM. J. OBSTETRICS AND
GYNECOLOGY 267.e1, 267.e3-.e4 (2013); Jason Luty et al., Is Opiate
Detoxification Unsafe in Pregnancy?, 24 J. SUBSTANCE ABUSE
TREATMENT 363, 365 (2003).
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second trimester or risk of premature labor in the third
trimester.107 Physician Robert Stewart and colleagues designed a
retrospective cohort study of 95 pregnant patients who elected to
undergo inpatient detoxification and found no cases of stillbirth
or fetal demise among the inpatient population.108 In one of the
largest studies examining pregnancy outcomes related to
detoxification, physician Jennifer Bell and colleagues assessed 301
pregnant patients with opiate addiction who elected to participate
in four methods of medically-assisted detoxification treatment.
Bell and colleagues found no increased risk of premature labor or
fetal demise associated with detoxification.109 Finally, in a
systematic review examining fifteen separate studies assessing
potential risks of detoxification that included hundreds of
patients, physician Mishka Terplan and colleagues concluded that
detoxification does not appear to contribute to rates of fetal
demise.110
This research suggests that not only does detoxification
constitute a safe option for both the pregnant patient and fetus,
but that successful detoxification is possible. Current research
shows detoxification without relapse at promising rates of success
ranging from 56%-82.6%.111 A comparison study conducted by
Bell and colleagues demonstrated that short-term inpatient
detoxification followed by intense behavioral health support
produced the most successful rates of recovery.112 The impact of

107. Luty et al., supra note 106.
108. Stewart et al., supra note 106, at e3. One case of fetal demise did
occur in a pregnant patient who was not undergoing detoxification,
refused MAT, and did not return for prenatal care. Id.
109. See Bell et al., supra note 102, at e3.
110. Mishka Terplan et al., Opioid Detoxification During Pregnancy: A
Systematic Review, 131 OBSTETRICS & GYNECOLOGY 803, 812
(2018).
111. Stewart et al., supra note 106, at e4-5 (finding 56% of pregnant
patients successfully detoxified without relapse); Dashe et al., supra
note 105, at 854 (finding 59% of pregnant patients successfully
detoxified without relapse); Bell et al., supra note 102 (finding
Group 2, pregnant patients who underwent inpatient detoxification
with intense behavioral therapy only relapsed at a rate of 17.4%,
or 82.6% remained successful).
112. Bell et al, supra note 102, at e3, tbl.1.
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behavioral therapy is significant.113 Bell and colleagues
demonstrated the stark difference in outcomes: whereas only
17.4% of pregnant patients who underwent inpatient
detoxification with intense behavioral therapy relapsed, 74% of
pregnant patients undergoing inpatient detoxification without
receiving behavioral therapy relapsed.114
In addition to the impact of behavioral therapy, Stewart and
colleagues considered what additional factors appeared to
contribute to successful detoxification without relapse and found
that a longer length of time the pregnant patient spent enrolled
in the inpatient facility corresponded to rates of success.115
Notably, Stewart and colleagues did not find a correlation
between maternal demographic characteristics, type of drug
abuse (intravenous versus ingestion), or years of prior drug abuse
and successful detoxification.116 These studies concluded that
detoxification with supportive measures requires substantial
commitment, but should be offered to all patients who do not
want to continue opioid use or want to reduce the risk of opioids
affecting the fetus.117
B.

Federal Policy Supporting MAT’s Efficacy Downplays
Significant Metrics

MAT may indeed work for some patients, particularly if the
patient tolerates the medication without adverse effects and the
provider offers comprehensive behavioral treatment. But
promoting MAT as the standard of care for all women with OUD,
especially while warning of dangers of detoxification, requires
critical analysis. Research analyzing the evidence behind MAT’s
efficacy among the general population and specific to pregnant
patients suggests several issues.118 Sources describing MAT’s
efficacy rely on partial metrics and omit discussion of problematic
113. See ACOG, supra note 12. It should be noted that the current
standard of care warning against poor outcomes and high rates of
relapse after detoxification generally refers to detoxification
without additional treatment. See id.
114. Bell et al., supra note 102.
115. Stewart et al., supra note 106, at e2-e3.
116. Id.
117. Id. at e5.
118. Drabiak, supra note 14, at 45-57.
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outcomes, including: high rates of continued opioid and
polysubstance abuse, potential for dependence or addiction to the
replacement medication, risk of serious physical and neurological
outcomes to the pregnant patient, and potential risks to the fetus
and infant above the risk of NAS.119
1.

Many Patients in MAT Continue Opioid Abuse and
Polysubstance Abuse

Statements asserting that MAT constitutes the most effective
treatment contain a number of potentially misleading caveats:
some studies support this proposition by comparing MAT to
detoxification without additional treatment120 and do not address
the significance of continued substance abuse.121 One commonly
cited study by physician Karen Sees and colleagues did compare
MAT against treatment (where the detoxification group was
required to attend therapy sessions), and reported that MAT
increased retention and reduced opioid use.122 Yet this claim
requires further scrutiny: despite a slight decrease in opioid use
among the MAT group, opioid use in both groups remained
“consistently high;” additionally, both groups continued
polysubstance abuse of both opioids and cocaine, which Sees and
colleagues noted “remains a concern.”123 Though rates of

119. See discussion supra Part II (B)(3).
120. Valerie Gruber et al., A Randomized Trial of 6-Month Methadone

Maintenance With Standard or Minimal Counseling Versus 21-Day
Methadone Detoxification, 94 DRUG & ALCOHOL DEPENDENCE 199,
203-04 (2008); Richard Mattick et al., Methadone Maintenance
Therapy Versus No Opioid Replacement Therapy for Opioid
Dependence (Review), COCHRANE DATABASE SYSTEMATIC
REVIEWS, 2009, at 1, 11.
121. But see Karen Sees et al., Methadone Maintenance vs 180-Day

Psychosocially Enriched Detoxification for Treatment of Opioid
Dependence: A Randomized Controlled Trial, 283 JAMA 1303,
1308 (2000). Each group had disparate therapy requirements: the
methadone maintenance group required 2 hours of psychosocial
therapy per week, while the detoxification group was required to
attend 3 hours of psychosocial therapy per week, 14 educational
sessions, and 1 hour of cocaine group therapy where appropriate
and therapy related to aftercare. Id.
122. Id.
123. Id. at 1303 (reporting the presence of other drugs from monthly
urinalysis); Id. at 1307-08 (a consistently high use of heroin among
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substance abuse vary over time and by study, rates of continued
opioid abuse among general population patients enrolled in MAT
range from over 50% to 89.5%, even after being enrolled in MAT
for several months.124 Indeed, addiction scientist Suzanne Nielsen
and colleagues concluded that there appears to be no significant
difference in days of unsanctioned opioid use among study groups
who receive MAT versus those who do not.125
Studies examining pregnant and parenting patients who
abuse heroin demonstrated similarly high rates of ongoing opioid
abuse. 49% -81% of patients did not merely relapse but engaged
in an ongoing pattern of injecting heroin several times per week.126
Importantly, high rates of continued substance abuse did not
appear to be related to maintenance dosing.127 This has led some
researchers to question whether MAT should still constitute the
standard of care for pregnant patients when they continue
ongoing substance abuse.128
Research cited to support the efficacy of MAT also
demonstrates consistently high rates of other types of

both groups); Id. at 1309 (noting that the rates of continued heroin
use among both groups remain a concern).
124. Gruber et al., supra note 120, at 203, tbl. 1 (citing 89.5% abuse of
opiates at 8.5 months); Sees et al., supra note 121 (citing over 50%
continued abuse of opiates at 12 months).
Nielsen et al., Opioid Agonist Treatment for
Pharmaceutical Opioid Dependent People (Review), COCHRANE

125. Suzanne

DATABASE SYSTEMATIC REVIEWS, 2016, at 1, 16.
126. Gary Hulse et al., The Relationship Between Maternal Use of
Heroin and Methadone and Infant Birth Weight, 92 ADDICTION
1571, 1573 (1997) (finding 49% of patients enrolled in MAT
continued to abuse heroin); Carolien Konijnenberg & Annika
Melinder, Prenatal Exposure to Buprenorphine: A Review of
Potential Effects on Cognitive Development, 17 CHILD
NEUROPSYCHOLOGY 495, 509 (2011) (citing 81% of parenting
women enrolled in MAT for heroin addiction self-reported abusing
heroin several times per week or on a more frequent basis since
their first child was born); Anne Kolar et al., Children of Substance

Abusers: The Life Experiences of Children of Opiate Addicts in
Methadone Maintenance, 20 AM. J. DRUG ALCOHOL ABUSE 159, 165
(1994).
127. Sees et al., supra note 121, at 1307-1308.
128. Hulse et al., supra note 126, at 1571.
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polysubstance abuse across study groups.129 Research shows both
the general patient population and pregnant patients enrolled in
MAT abuse multiple other licit and illicit substances in addition
to opioids, including alcohol, cocaine, and marijuana.130 Addiction
scientist Hendrée Jones and colleagues found varying rates of
polysubstance abuse based on treatment group, finding that up
to 57% of pregnant patients receiving methadone maintenance
continued to abuse cocaine, and up to 48% continued to abuse
marijuana.131 Additional research specifically studying pregnant
and parenting patients demonstrates similarly high rates of
polysubstance abuse, ranging from 56% up to 81% of patients
who supplemented their opioid replacement with illicit
substances.132
Discounting high rates of continuing opioid or polysubstance
abuse among persons enrolled in MAT should trigger a reassessment of blanket declarations of efficacy. Evidence of high
rates of polysubstance abuse also allows healthcare providers to
foresee that many pregnant and parenting women enrolled in
MAT will continue polysubstance abuse.
2.

The Problem of Refusing Treatment: Not All Pregnant
Patients with SUD Want Treatment

In addition to patients who continue substance abuse while
enrolled in MAT, a sizable portion of patients refuse treatment,
leave MAT, or disappear and do not return for any medical
129. See Gruber et al., supra note 120, at 202-204; see also Miriam
Mintzer & Maxine Stitzer, Cognitive Impairment in Methadone
Maintenance Patients, 67 DRUG & ALCOHOL DEPENDENCE 41, 43
(2002).
130. Mintzer & Stitzer, supra note 129 (citing subjects enrolled in MAT
self-reported the following polysubstance abuse: 50% continued to
abuse heroin, 44% abused cocaine, and 28% abused cannabis).
131. Hendrée Jones et al., Methadone Maintenance v. Methadone Taper
During Pregnancy: Maternal and Neonatal Outcomes, 17
AM. J. ON ADDICTIONS 372, 379 (2008).
132. Lauren Jansson et al., Maternal Buprenorphine Treatment and
Infant Outcome, 180 DRUG & ALCOHOL DEPENDENCE 56, 60 (2017)
(citing 56% of pregnant women had positive toxicology tests to
indicate polysubstance abuse during enrollment in MAT); Stewart
et al., supra note 106, at e1, e3 (citing 71% of pregnant patients
enrolled in MAT continued to engage in polysubstance abuse);
Konijnenberg & Melinder, supra note 126 (citing 81% of parenting
patients continued abusing heroin).
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care.133 In a Cochrane Review, epidemiologist Silvia Minozzi and
colleagues conducted a systematic review of studies specifically
looking at pregnant patients with SUD enrolled in MAT
prescribed methadone or buprenorphine.134 Minozzi and
colleagues found high rates of attrition across multiple studies:
30-40% of women enrolled in MAT left treatment.135
While some patients leave treatment, other women with SUD
do not enter treatment at all. Some stakeholders frame the issue
as a matter of access, asserting that access to quality treatment
would ameliorate the number of pregnant patients with SUD who
continue substance abuse or who do not seek treatment.136 While
this may apply in some instances, one study by social science
researchers Afton Jackson and Lisa Shannon found that only
25.9% of women listed availability of treatment as a barrier
preventing them from seeking treatment.137 Jackson and Shannon
also found that about 15% of women with SUD did not want
treatment at all.138 These findings should raise multiple questions,
such as whether women should be provided assistance to stop
substance abuse by other supportive resources, or whether
treatment includes sufficient resources for pregnant and parenting
patients (such as providing childcare, education, parenting
classes, job training, and family counseling).139
133. Stewart et al., supra note 106, at e3; Minozzi et al., supra note 20,
at 2-7.
134. Minozzi et al., supra note 20, at 2-7.
135. Id.
136. Afton Jackson & Lisa Shannon, Barriers to Receiving Substance
Abuse Treatment Among Rural Pregnant Women in Kentucky, 16
MATERNAL CHILD HEALTH J. 1762, 1763 (2012).
137. Id. at 1767; see also Marilyn Daley et al., Substance Abuse
Treatment for Pregnant Women: A Window of Opportunity? 23
ADDICTIVE BEHAVIORS 239-49 (1998) (finding that for some
pregnant women, an increased access to care does not necessarily
translate to better treatment outcomes).
138. Jackson & Shannon, supra note 136, at 1767.
139. Id.; see also Katherine Davis & Kimberly Yonkers, Making

Lemonade Out of Lemons: A Case Report and Literature Review
of External Pressure as an Intervention with Pregnant and
Parenting Substance Using Women, 73 J. CLINICAL PSYCHIATRY
51-55 (2012) (describing family centered treatment care, the
possibility of residential facilities where pregnant and parenting
patients can live with their children, and therapeutic communities).
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Women with SUD who engage in ongoing substance abuse,
with no desire to stop, should prompt researchers, clinicians, and
policymakers to consider whether coercion and incentives that
motivate women to stop substance abuse and engage in treatment
should be considered. Some research indicates that pregnant
patients can and do respond to incentives and pressure, such as
warnings or mandates to enter treatment.140 For women in
treatment whose children had been removed by Child Protective
Services (CPS), linking successful engagement in treatment and
stopping substance abuse with regaining custody of their child
served as a powerful motivating factor.141 Finally, women in
treatment reporting external pressure not only remained in
treatment for a longer duration, but reported fewer days of
substance abuse.142 These women were also twice as likely to have
negative toxicology screens.143
3.

MAT Does Serve as Medically Sanctioned Substitute Opioid
with Serious Risks for Dependency

Despite rhetoric in federal policy asserting that MAT does
not constitute replacement or substitution of one addiction for
another,144 these claims are not supported by pharmacology, legal
classification by the DEA, or warnings on FDA-approved package
information. As opioid agonists, both methadone and
buprenorphine occupy the same receptors as other opioids such
as heroin or oxycodone.145 Though NIDA denies that patients
receiving methadone and buprenorphine experience euphoria,
140. Davis & Yonkers, supra note 139.
141. Id. (finding that mothers who entered treatment were more likely
(60.6%) to be reunified with their children than mothers who did
not enter treatment (35.5%)).

External Pressure, Motivation, and
Treatment Outcomes Among Pregnant Substance Abusing
Women, 107 DRUG & ALCOHOL DEPENDENCE 149, 151 (2010).

142. Steven Ondersma et al.,

143. Id.
144. See discussion supra Part B. Federal Policy Supporting MAT.
145. METHADOSE, supra note 29; SAMHSA Methadone, supra note
30; SUBUTEX supra note 42; Buprenorphine, SUBSTANCE ABUSE &
MENTAL HEALTH ADMIN., https://www.samhsa.gov/medicationassisted-treatment/medications-counseling-related-conditions/
buprenorphinebuprenorphine [https://perma.cc/HWS5-3FYK] (last
visited Feb. 9, 2022) (hereinafter SAMHSA Buprenorphine).
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both FDA and DEA product labeling caution that both controlled
substances are capable of producing significant euphoria even in
persons with tolerance.146 In a graph illustrating sustained
activation of opioid receptors (euphoria), NIDA compares the
relative euphoria of heroin to methadone, buprenorphine, and
naltrexone.147 The graph shows that buprenorphine, as a partial
opioid agonist, produces less euphoria than heroin, but also shows
that methadone produces the same level of euphoria as heroin
and sustains this activation for a longer duration than heroin.148
Research also indicates that MAT may not reduce cravings.
Many persons enrolled in MAT abuse the prescribed agonist itself
(e.g. injecting methadone or buprenorphine) in addition to
continuing concurrent polysubstance abuse.149 This suggests a
deficiency in the premise of MAT – patients are still experiencing
a compulsion and drive to abuse drugs, including the prescribed
opioid agonist, for pharmacological effect.
4.

Patients Still May Struggle with Impairment and Activities of
Daily Life

Pregnant and parenting women enrolled in MAT who
continue ongoing substance abuse may also face barriers to
psychosocial functioning, employment, and parenting ability.
Many studies use retention in treatment as a metric of success,
but presuming treatment retention equates to success reveals
conflicting and troubling evidence.150 While addiction scientist
Richard Mattick and colleagues assert that MAT constitutes an
effective intervention, their comprehensive review found no
146. Id.
147. MEDICATIONS TO TREAT OPIOID USE DISORDER, supra note 24.
148. Id.
149. See Hanna Uosukainen et al., Twelve-Year Trend in Treatment
Seeking for Buprenorphine Abuse in Finland, 127 DRUG &
ALCOHOL DEPENDENCE 207, 211 (2013) (over 80% of subjects
enrolled in MAT injected buprenorphine and describes rates of
concurrent polysubstance abuse); see also Michelle Lofwall &
Sharon Walsh, A Review of Buprenorphine Diversion and Misuse:

The Current Evidence Base and Experiences from Around
the World, J. ADDICTION MEDICINE, 2014, at 1, 6 (citing varied
research that 18-28% of persons enrolled in methadone or
buprenorphine maintenance programs have shared, sold, or given
away their prescribed medication).
150. See Mattick et al., supra note 120.
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statistically significant differences in criminal involvement or
mortality.151 Several studies conflict with the Surgeon General’s
claims that MAT helps persons return to a productive life, finding
continued psychosocial dysfunction and rates of marginal
employment or unemployment.152 One key barrier to employment
and psychosocial functioning rests upon patients’ ability to
conduct activities of daily living, such as driving, working, going
to school, and engaging in family life, without significant
impairment such as experiencing euphoria, craving, intoxication,
and symptoms of withdrawal.153
Multiple media reports question pregnant and parenting
patients’ abilities to conduct activities of daily life while enrolled
in MAT based on accounts of ongoing polysubstance abuse,
intoxication, and impairment.154 Samantha Jones exemplified the
grim impact of continued polysubstance abuse in multiple
contexts.155 Despite Jones’ enrollment in MAT, while abusing a
variety of prescribed and illicit drugs, she lost consciousness in
her vehicle with her other child in the back seat.156 She abused
multiple prescribed and illicit substances throughout her
pregnancy with Remington; and transferred a toxic amount of
drugs to Remington while breastfeeding—ultimately causing his
death.157

151. Id.
152. Sees et al., supra note 121, at 1309; Julie Harris & Karen McElrath,

Methadone as Social Control: Institutionalized Stigma and the
Prospect of Recovery, 22 QUALITATIVE HEALTH RSCH. 810, 818
(2012) (discussing barriers to societal reintegration and how many
MAT patients are still unemployed or marginally employed).
153. Lisa Torres, Risk Management: Patient Safety; Public Safety and
OTP Liability, SUBSTANCE ABUSE & MENTAL HEALTH ADMIN.
[hereinafter “SAMHSA Risk Management”] (on file with author).
154. Kounang, supra note 1; Laviola, supra note 2.
155. Kounang, supra note 1; Laviola, supra note 2.
156. Simon Veazey, Pennsylvania Mother Whose Drugs-Laced Breast
Milk Killed Her Baby Will Not Be Jailed, Epoch Times (May 9,
2019),
https://www.theepochtimes.com/pennsylvania-motherwhose-drugs-laced-breast-milk-killer-her-baby-will-not-bejailed_2913419.html [https://perma.cc/R62J-7MTU].
157. Kounang, supra note 1; Laviola, supra note 2.
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Other cases with similar facts - mothers who continue to
engage in polysubstance abuse, suffer from extreme somnolence,158
lose consciousness, and accidentally cause their child’s death have also garnered media attention.159 Amanda McKenzie
described her prescription for methadone as “10 times stronger
than any pill.”160 Its impact was more powerful than she expected
and she fell asleep in the bathtub with her infant son, who died
as a result of accidental drowning.161 Intoxication, impairment,
accidents, and infant deaths not only raise serious concerns for
the pregnant and parenting women’s ability to go about daily life
and care for their children. These issues implicate criminal
liability considerations when these mothers’ actions cause their
child’s death.

III. RE-ASSESSING RISKS AND BENEFITS OF MAT TO THE
MATERNAL-INFANT DYAD
This section explores the less discussed, yet centrally
important, side effects and risks of MAT, specifically to the
maternal-infant dyad for prenatal and parenting patients. First,
this section will describe the effects of opioid agonist medications
on patients’ physical well-being, neurological function, and
158. Lauren Jansson & Martha Velez, Lactation and the SubstanceExposed
Mother-Infant
Dyad,
29
J.
PERINATAL
&
NEONATAL NURSING 277, 278 (2015) (describing the impact of
maternal somnolence on the mother’s ability to breastfeed and
care for her infant).
159. Duff Wilson, A Hospital Fails to Test for Drugs; A Day Later, A
Newborn is Dead, REUTERS (Dec. 7, 2015), https://www.
reuters.com/article/us-baby-opioids-pederson/hospital-fails-totest-for-drugs-days-later-a-newborn-is-dead-idUSKBN0TQ2RH20
151208 [https://perma.cc/R7MZ-GER6]; Duff Wilson & John
Shiffman, Newborns Die After Being Sent Home With Mothers
Struggling To Kick Drug Addictions, REUTERS (Dec. 7, 2015),
https://www.reuters.com/investigates/special-report/babyopioids/#article-1-unprotected [https://perma.cc/L6NN-R2AM];
Duff Wilson, As Social Services Stand Back, A Mother and Her
Baby Fall ‘Through the Canyon Into Hell’, REUTERS (Dec. 7,
2015), https://www.reuters.com/investigates/special-report/babyopioids/#article-2-failures-to-act [https://perma.cc/E8TL-Y72X].
160. Wilson, As Social Services Stand Back, A Mother and Her Baby
Fall ‘Through the Canyon into Hell’, supra note 159.
161. Id.
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psychological function, articulating how these risks take on
particular significance in the context of parenting patients with
infants and children. Second, this section will explore research
describing the variety of developmental, physical, and
neurological risks to the infant from prenatal opioid exposure.
Next, this section explores the postpartum period when the infant
is born, providing specific points for clinicians to consider.
A. Risks for the Patient: MAT Can Produce Physical,
Neurological, and or Psychological Harm that Hinders Recovery

Research suggests that the extensive side effects and adverse
effects of methadone and buprenorphine used in MAT should not
be dismissed as infrequent. Prescribed medications used in MAT
– even if patients do not engage in polysubstance abuse – may
still exert significant influence on patients’ quality of life. In one
study, over half of patients enrolled in methadone maintenance
programs experienced depression, fatigue, and headaches, which
negatively impacted patients’ subjective assessments of quality of
life.162 Even in cases where patients appear to be functioning
socially and engaged in activities of daily life, addiction scientist
Benedikt Fischer asserts that metrics of success should include
the patients’ own subjective assessments of how they feel.163
Fischer points to the “critical, yet often ignored” dysphoric
impact of methadone, wherein some patients describe the
influence of methadone as “discomforting, disabling, numbing and
tiring.”164
In addition to patients’ subjective assessments of how they
feel when taking medications in MAT as prescribed, opioid
agonists also pose risks to neurological and or psychological
functioning. Physician Wei-Che Lin and colleagues demonstrated
that patients enrolled in MAT who received an opioid agonist
experienced prominent adverse effects on multiple cognitive
functions, increased rates of depression and suicide, and a lower
162. Janie Sheridan et al., Health Problems and Help-Seeking Activities

of Methadone Maintenance Clients and Auckland Methadone
Services: A Potential for Community Pharmacy Expansion, 2
HARM REDUCTION J. 1, 4 (2005).
163. Benedikt Fischer et al., Eyes Wide

Shut? A Conceptual and Empirical Critique of Methadone
Maintenance Treatment, 11 EUROPEAN J. ADDICTION RES. 1, 2
(2005).
164. Id. at 4.
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quality of life.165 Opioid agonists negatively impact memory
processing, impair short term memory, impair visuo-spatial
attention, and reduce cognitive speed.166 Research shows that
opioid agonists produce changes in both white matter and gray
matter in the brain, resulting in structural and functional
abnormalities.167 Chronic exposure to opioid agonists may lead to
apoptosis (death) of neuronal cells and demyelination (impaired
connectivity within the brain’s synapses), which has been
connected to behaviors including impulsivity, lack of self-control,
and intolerance for cognitive complexity.168 Notably, research
correlates this neurological damage to duration and dose of MAT,
not pre-existing differences or damage from illicit opioid abuse.169
Wei Li and colleagues summarize these findings as evidence that
MAT induces a type of brain disease that may substantially
impair enrolled patients.170 This research suggests that MAT does
not promote neurological recovery, but rather extends
neurological dysfunction and may hinder behavioral therapy
options that rely on new neurological growth, cognitive judgment,
and discernment.
165. Wei-Che Lin et al., White Matter Abnormalities Correlating With

Memory and Depression in Heroin Users Under Methadone
Maintenance Treatment, PLOS ONE, Apr. 2012, at e33809, e33809;
see also Mintzer & Stitzer, supra note 129, at 46-47 (finding
patients enrolled in MAT had significantly worse performance than
controls on tests for memory and cognitive speed); Shane Darke et
al., Comparative Patterns of Cognitive Performance Amongst

Opioid Maintenance Patients, Abstinent Opioid Users and Opioid
Nonusers, 126 DRUG & ALCOHOL DEPENDENCE 309, 312-13 (2012)
(finding no substantive differences between patients using
methadone or buprenorphine where both groups had similar poor
performance and finding that patients enrolled in MAT had worse
cognitive performance than both controls and former opioid users
who were not abstinent).
166. Darke et al., supra note 165.
167. Wei Li et al., Methadone Induced Damage to White Matter

Integrity in Methadone Maintenance Patients: A Longitudinal
Self-Control DTI Study, NATURE SCIENTIFIC REPORTS, 2016, at 1,
5.
168. Id. at 2, 5; Darke et al., supra note 165, at 309; Mintzer & Stitzer,
supra note 129, at 46-47; Lin et al., supra note 165, at 1, 7.
169. Li et al. supra note 167, at 3-4; Darke et al., supra note 165, at 312;
Lin et al., supra note 165, at 1, 7.
170. Li et al., supra note 167, at 5.
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These neurochemical changes in the maternal brain relating
to impulsivity, attention, emotional regulation, and risk taking are
particularly salient during the postpartum period.171
Facing physical recovery from childbirth, sleep deprivation,
and the stress of parenting a new infant, executive regulation
constitutes a core component of maternal behavior.172 In animal
models, opioids markedly impact maternal behavior by disrupting
maternal bonding, attention, and responsiveness to cues, both
based on maternal drug seeking behaviors and the
pharmacological impact of the drug on the mother’s ability to
care for her young.173 Indeed, physicians Jansson and Velez
caution that physicians prescribing MAT to parenting mothers
must consider the effects of both MAT and the possibility of
ongoing substance abuse on the mother’s ability to parent.174
Even when taken as prescribed, opioid agonist medications
can result in maternal somnolence, or extreme sedation and
tiredness.175 This is compounded by normal postpartum sleep
deprivation.176 Falling asleep or becoming unconscious has
apparent risk when in a vehicle,177 but somnolence also impacts
the mother’s ability to breastfeed and whether she can: position
the infant safely; respond to infant cues of tiredness, hunger and
comfort; make effective judgments; and accurately assess risks.178
171. See Anna Fodor et al., Behavioral Effects of Perinatal Opioid
Exposure, 104 LIFE SCIENCES 1, 5 (2014) (discussing opioids effect
on animal maternal behavior); Jansson & Velez, supra note 158, at
279-79.
172. Jansson & Velez, supra note 158, at 278-79.
173. Fodor et al., supra note 171.
174. Jansson & Velez, supra note 158, at 284.
175. ACOG, supra note 12.
176. Id.
177. See, e.g., Petr Svab, Opioid Epidemic: Mother, Father, Found in
Car Unconscious, Their Baby in Back Seat, EPOCH TIMES (Oct. 25,
2017), https://www.theepochtimes.com/opioid-epidemic-motherfather-found-in-car-unconscious-their-baby-in-back-seat_2341941.
html [https://perma.cc/59KX-PRXA]; Wilson & Shiffman,

Newborns Die After Being Sent Home With Mothers Struggling
To Kick Drug Addictions, supra note 159; Veazey, supra note 156.
178. See, e.g., Wilson & Shiffman, Newborns Die After Being Sent Home
With Mothers Struggling To Kick Drug Addictions, supra note
159.
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Adverse effects listed on FDA package information, neurological
research, and patient accounts suggest that even patients who
attempt to engage in treatment and take the medication as
prescribed may encounter significant barriers potentially
hindering their recovery and ability to effectively parent their
infant.
B.

Risks to the Developing Fetus and Infant

Although federal policy and current guidelines recognize the
risks of NAS, this constitutes a profoundly narrow view of the
potential risks to the fetus and infant. SAMHSA and ACOG
assert that MAT does not increase risk of birth defects, minimally
affects neurodevelopment, and the benefits of MAT outweigh the
risks of untreated addiction.179 However, several scholarly articles
suggest evidence of the negative effects of MAT on the developing
fetus.180 Though many scientists and scholars concede
developmental harms of prenatal drug abuse, multiple
stakeholders still deny inherent risk of prenatal substance abuse
on the developing infant.181 Such a position stands in stark
contrast to current research that shows prenatal substance use –
even taking prescribed opioids – poses serious risks to the

179. U.S. SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN.,
CLINICAL GUIDANCE FOR TREATING PREGNANT AND PARENTING
WOMEN WITH OPIOID USE DISORDER AND THEIR INFANTS (2018);
ACOG, supra note 12.
180. See generally Fodor et al., supra note 171; Adriana Forray & Dawn
Foster, Substance Use in the Perinatal Period, CURRENT PSYCH.
REP., 2015, at 1; Egil Nygaard et al., Longitudinal Cognitive

Development of Children Born to Mothers with Opioid and
Polysubstance Abuse, 78 PEDIATRIC RES. 330 (2015); Elizabeth
Byrnes & Fair Vassoler, Modeling Prenatal Opioid Exposure in
Animals: Current Findings and Future Directions, FRONT
NEUROENDOCRINAL, 2018, at 1; Behnke & Smith, supra note 15;
Kristine Walhovd et al., Child Neuroanatomical, Neurocognitive,
and Visual Acuity Outcomes with Maternal Opioid and
Polysubstance Detoxification, 52 PEDIATRIC NEUROLOGY 326
(2015).
181. See, e.g. Lynn Paltrow, Governmental Responses to Pregnant
Women Who Use Alcohol or Other Drugs, 8 DEPAUL J. HEALTH
CARE L. 461, 462 (2005); Cortney Lollar, Criminalizing Pregnancy,
92 INDIANA L.J. 947, 967 (2017); BISHOP ET AL., supra note 17, at
12-13.
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developing infant.182 Substance use can impact growth,
neurological development, and cognitive development, as well as
increase the risk of infant morbidity and mortality.183
1.

Dangers of Denying Harm from Maternal Substance Abuse

During the crack cocaine epidemic of the 1990s, legal scholars
and health professionals were divided on how best to respond to
the problem of prenatal substance abuse.184 Many legal scholars
acknowledged the potential risks of prenatal substance abuse on
fetal health and agreed it should be minimized.185 However, some
legal scholars, health professionals, and media reports adopted
the narrative that the war on drugs was another extension of the
war on women,186 asserting that reports of infant harm from the
crack cocaine epidemic were hyperbolic and misleading.187 Legal
scholar, Cortney Lollar, characterizes the concerns about prenatal
substance abuse as the “fetal harm fallacy,” arguing that such
fears were unfounded and that any potential effects were
relatively small and limited to short term duration.188 According
to some scholars, researchers “debunked” this “myth” in the vast
majority of cases, showing that exposure to illicit drugs does not

182. See sources cited supra note 180.
183. See sources cited supra note 180.
184. See Barry Lester et al., Substance Use During Pregnancy: Time for
Policy to Catch Up with Research, HARM REDUCTION J., 2004., at
1, 2-3.
185. Id. at 11-13.
186. Nina Martin, This Law is Supposed to Protect Babies, But It’s
Putting Their Moms Behind Bars, MOTHER JONES (Sept. 23, 2015),
https://www.motherjones.com/politics/2015/09/alabamachemical-endangerment-drug-war/
[https://perma.cc/G9AT7A6X].
ET AL., supra note 17, at 13; Mina Dixon Davis, “Bad
Moms” and Powerful Prosecutors: Why a Public Health Approach
to Maternal Drug Use is Necessary to Lessen the Hardship Borne
by Women in the South, 25 GEO. J. ON POVERTY L. & POL’Y 305,
310-11 (2018); Lollar, supra note 181, at 954; Jennifer Egan,
Children of the Opioid Epidemic, N.Y. TIMES MAG. (May 9, 2018),

187. BISHOP

https://www.nytimes.com/2018/05/09/magazine/children-of-theopioid-epidemic.html [https://perma.cc/6Y2L-7ZNA].
188. Lollar, supra note 181, at 953-54.
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cause long term harm.189 Legal activist Lynn Paltrow declared
that poverty exerts more of a detrimental impact on fetal health
than illicit drugs.190 Extending this premise further, some
stakeholders argued that the focus on maternal substance abuse
is not based on scientific evidence, but instead merely a
demonization of women of low socioeconomic standing, motivated
by racial animus.191 Finally, legal scholars and even the ACOG
attempt to undermine causality for infant harm by asserting that
other factors, such as prenatal diet, parenting, and licit
substances such as prescribed drugs, alcohol, and tobacco exert
far greater harm.192
2.

Scientific Evidence Demonstrates Risk of Significant Harm
from Opioid Use During Pregnancy

Asserting that concerns about maternal substance abuse are
merely alarmist myths is unsupported by scientific evidence.193
Further suggesting they are motivated by race or class bias is not
only misleading, but factually incorrect.194 Current evidence
demonstrates maternal opioid use during pregnancy – both illicit

189. Id. at 951-54; BISHOP
note 187.

ET AL.,

supra note 17, at 6-7; Davis, supra

190. Paltrow, supra note 181; Davis, supra note 187.
191. Lollar, supra note 181, at 954; BISHOP ET AL., supra note 17, at 67; Egan, supra note 187.
192. Paltrow, supra note 181 (stating poverty has more of an impact on
the developing infant and infants that are born to low
socioeconomic status are exposed to the same neurological risks as
infants exposed prenatally to cocaine); Lollar, supra note 181, at
952 (stating smoking, alcohol, and prescription drugs are more
harmful to the developing infant than prenatal substance abuse);
Catherine Monk et al., Maternal Prenatal Distress and Poor

Nutrition – Mutually Influencing Risk Factors Affecting Infant
Neurocognitive Development, 54 J. CHILD PSYCH. & PSYCHIATRY
115, 115 (2013) (stating that the environment, including the
maternal diet and psychological state, affect a child’s
neurodevelopment); Lisa A. Serbin, The Influence of Parenting on
Early Childhood Health and Health Care Utilization, 39 J.
PEDIATRIC PSYCH. 1161, 1169-70 (2014) (finding that greater
parental support was linked to better heath).
193. See supra note 181.
194. Id.
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abuse and use as prescribed pursuant to MAT – exerts a variety
of effects on the fetus.195
Opioids readily cross the placenta and enter the fetal
bloodstream, impacting fetal growth, cell development, and
neurological and neurotransmitter development.196 Maternal
opioid use and abuse also impacts blood flow to the fetus and
alters the delivery of nutrients during fetal development.197
Opioids are modulatory, which means that they influence cellular
growth, maturation, and neurological development both
prenatally as well as throughout the infant’s life.198 Only a few
studies have examined long term outcomes for people prenatallyexposed to opioids, and many long term consequences are
unknown.199 Some researchers suggest that opioids may exert an
epigenetic influence (turning on or off certain genes that increase
risk of disease) during fetal development, which would influence
the physiology and behavior of future descendants.200
a.

Physical Risks to Infants Arising from Prenatal Opioid
Exposure

Despite federal policy stating without treatment, pregnant
women with OUD face increased risks of preterm delivery or low

195. Id.
196. Federica Gilardi et al., Will Widespread Synthetic Opioid

Consumption Induce Epigenetic Consequences in Future
Generations, FRONTIERS IN PHARMACOLOGY, 2018, at 1, 4 (stating
opioids

readily

cross

the

placenta);

Emily

Ross

et

al.,

Developmental Consequences of Fetal Exposure to Drugs: What
We Know and What We Must Still Learn, 40
NEUROPSYCHOPHARMACOLOGY 61, 61-62 (2015) (stating how
opioids readily cross the placenta and affect fetal brain
development); Behnke & Smith, supra note 15, at e1012
(describing how opioid cross the placenta and exert influence on
fetal growth and development).
197. Ross et al., supra note 196, at 62; Behnke & Smith, supra note 15,
at e1012.
198. Kurt Hauser & Pamela Knapp, Opiate Drugs with Abuse Liability

Hijack the Endogenous Opioid System to Disrupt Neuronal and
Glial Maturation in the Central Nervous System, FRONTIERS
PEDIATRICS, 2018, at 1, 2.
199. Gilardi et al., supra note 196, at 4.
200. Id. at 2.
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infant birth weight,201 but this comparison measures infants
exposed to MAT versus infants born to mothers with untreated
addiction, not healthy controls or infants born to mothers who
underwent detoxification.
Although some assert infants exposed to MAT follow normal
developmental trajectories,202 robust research demonstrates that
prenatal opioid exposure results in a lower infant birth weight,203
decreased head circumferences,204 decreased body length,205 and
decreased brain volume.206 Research suggests these differences in
growth persist throughout childhood, affecting the child’s growth
and size.207
Even controlling for polysubstance abuse, one study by
Jansson and colleagues examined the impact of prenatal
buprenorphine exposure.208 It found that higher maternal doses of

201. Hulse et al., supra note 126, at 1577; Federal Guidelines for Opioid
Treatment Programs, infra note 264.
202. Karol Kaltenbach et al., Prenatal Exposure to Methadone or
Buprenorphine: Early Childhood Developmental Outcomes, 185
DRUG & ALCOHOL DEPENDENCE 40, 47 (2018). Kaltenbach and
colleagues assert infants exposed to opioids in MAT follow a path
of normal development with the average range and normal limits.
The authors cite that mothers report increasing behavioral
difficulties with their children and developmental problems but the
authors attribute these reports to deficiencies in parent-child
relationship rather than the impact of prenatal opioid exposure. Id.
The study authors received funding from Reckett Benkiser (now
Invidior) manufacturer of buprenorphine formulations used in
MAT. Id. at 48.
203. Nygaard et al., supra note 180, at 330; Forray & Foster, supra note
180; Ross et al., supra note 196, at 66; Konijnenberg & Melinder,
supra note 126, at 497; Mette Norgaard et al., Birth and Neonatal

Outcomes Following Opioid Use in Pregnancy: A Danish
Population-Based Study, 9 SUBSTANCE ABUSE: RSCH. & TREATMENT
5, 5 (2015); Megan Thomas et al., Medication Assisted Treatment
in Pregnancy and Neonatal Anthropometrics, 131 OBSTETRICS &
GYNECOLOGY 136S, 136S (2018).
204. Konijnenberg & Melinder, supra note 126, at 497; Ross et al., supra
note 196, at 66; Thomas et al., supra note 203.
205. Konijnenberg & Melinder, supra note 126, at 497.
206. Id. at 498.
207. Id. at 497.
208. Jansson et al., supra note 132, at 56.
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buprenorphine corresponded with lower infant birth weights.209 In
another study, neuropsychologist Kristine Walhovd and
colleagues examined whether decreased brain volume in infants
resulting from prenatal exposure to opioids and polysubstance
abuse would decrease over time if children were raised by
supportive adoptive parents.210 Walhovd and colleagues still
found persistent lower brain volumes of children living in
supportive homes who were prenatally exposed to opioids.211
Prenatal opioid exposure affects a variety of physical
attributes, such as increasing the risk of cardiac malformation,212
infant respiratory insufficiency,213 decreased visual acuity,214
strabismus (crossed eyes),215 and risk of preterm birth two- to
three-fold.216 Fodor and colleagues assert that MAT is not
without substantial risks, as it also increases the risk of Sudden
Infant Death Syndrome, risk of stillbirth, and rate of infant
mortality.217
b.

Neurological Risks to Infants Associated with Prenatal Opioid
Exposure

In addition to physical growth differences, increased risk of
morbidities, and increased risk of infant mortality, prenatal opioid
209. Id.
210. Kristine B. Walhovd et al., Volumetric Cerebral Characteristcis of
Children Exposed to Opiates and Other Substances in Utero, 36
NEUROIMAGE 1331, 1332 (2007).
211. Id. at 1342-43.
212. Norgaard et al., supra note 203, at 9; Gilardi et al., supra note 196,
at 5.
213. Austin D. Hocker et al., Maternal Methadone Destabilizes Neonatal

Breathing and Desensitizes Neonates to Opioid-Induced
Respiratory Frequency Depression, 12 FRONTIERS IN PHYSIOLOGY
1, 1 (2021).
214. Walhovd et al., supra note 180, at 326.
215. Sylvia H. Yoo, Lauren M. Jansson, & Hee-Jung Park, Sensorimotor
Outcomes in Children with Prenatal Exposure to Methadone, 21 J.
AM. ASS’N PEDIATRIC OPTHALMOLOGY & STRABISMUS 316, 316
(2017).
216. Norgaard et al., supra note 203, at 10; Ross et al., supra note 196,
at 64.
217. Fodor et al., supra note 171, at 2; Forray & Foster, supra note 180,
at 8.
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exposure hinders normal neurological development and
maturation.218 Addiction psychologists Carolien Konijnenberg
and Annika Melinder note that prenatal opioid exposure occurs
during rapid growth, a critical window of neurological
development in which the developing fetus is particularly
vulnerable.219 Research shows that prenatal opioid exposure
detrimentally affects learning,220 cognition,221 memory,222 and
executive function (goal-directed behaviors, planning, decisionmaking) in both young children and school aged children.223 In
addition, prenatal exogenous opioid exposure alters endocrine
function, modifying the infant’s hormonal development in
sexually dimorphic brain regions, and in adults, impacts social and
reproductive behavior.224
While some scientists and stakeholders theorize that the
observed differences in neurological development and cognition
are only attributable to social and environmental factors rather
than prenatal opioid exposure,225 research does not support this
stance. Even when prenatally-opioid-exposed children are
adopted into what researchers characterize as supportive homes—
they still demonstrate lower brain maturation and cognitive
function compared to healthy controls.226 Importantly, prenatal
218. Eivind Sirnes et al., Brain Morphology in School-Aged Children
with Prenatal Opioid Exposure: A Structural MRI Study, 106-107
EARLY HUM. Dev., 33, 33 (2017).
219. Konijnenberg & Melinder, supra note 126, at 500.
220. Sirnes et al., supra note 218 (describing impaired learning ability);
Byrnes & Vassoler, supra note 180, at 7 (describing impaired spatial
learning ability).
221. See Walhovd et al., supra note 180, at 330 (describing lower
cognitive scores); Nygaard et al., supra note 180, at 333 (measuring
lower cognitive scores); Sirnes et al., supra note, 218, at 33
(measuring lower cognitive scores).
222. Behnke & Smith, supra note 15, at e1015 (impaired short term
memory); Fodor et al., supra note 171, at 3 (in animal models,
prenatally opioid exposed animals experiences demonstrated
impairment in short term memory).
223. Byrnes & Vassoler, supra note 180, at 7; Nygaard et al., supra note
180, at 331.
224. Ross et al., supra note 196, at 65.
225. Sirnes et al., supra note 218, at 33.
226. Walhovd et al., supra note 180, at 326.
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opioid exposure exerts a lasting impact on children’s cognitive
abilities: differences in cognition persist over time, and one study
by psychologist Egil Nygaard and colleagues demonstrated that
decreases in cognition actually increased over time.227
Research suggests that prenatal opioid exposure not only
decreases neuroanatomical volume and cognitive function, but
may alter the neurochemical and morphological maturation of the
brain.228 Prenatal exposure to opioids leads to both reduced brain
volume and structural deficits in certain areas of the brain, such
as the basal ganglia (responsible for learning, cognition, and
emotional processing).229 These differences persist even when
controlling for lower birth weight, which researchers theorize
results from opioids’ influence on apoptosis (cell death) in the
brain.230 Multiple studies also demonstrate prenatal opioid
exposure influences neurotransmitter development, myelination
(neurotransmitters’ ease and ability to communicate),231 and
synaptic
organization
(optimal
neurotransmitter
communication).232
c.

Implications of Risks to Infants Associated with Prenatal
Opioid Exposure

Some
research
suggests
these
perturbations
in
neurotransmitter development may increase risk of depression, or
alternatively, increase risk of inattention, hyperactivity,
impulsivity, and aggression.233 Exposure to exogenous opioids
combined with variations in neurotransmitter development and
organization may also impact the brain’s ability to produce
endogenous opioids, which may correlate to drug-seeking behavior

227. Nygaard et al., supra note 180, at 330.
228. Hauser & Knapp, supra note 198, at 8; Sirnes et al., supra note 218,
at 34.
229. Hauser & Knapp, supra note 198, at 8; Sirnes, supra note 218, at
35.
230. Walhovd et al., supra note 180, at 330; Ross et al., supra note 196,
at 65.
231. Fodor et al., supra note 171, at 3; Byrnes & Vassoler, supra note
180, at 4; Konijnenberg & Melinder, supra note 126, at 503.
232. Konijnenberg & Melinder, supra note 126, at 505.
233. Fodor et al., supra note 171, at 3; Behnke & Smith, supra note 15,
at e1015.
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later in life.234 Importantly, variations in endogenous opioids
combined with impulsivity and impairment of executive function
such as self-control and goal-directed behaviors lead researchers
to hypothesize that prenatally-exposed infants may be at an
increased risk for addiction during adolescence and adulthood.235
Walhovd and colleagues demonstrated the impact of
residential detoxification and reduced prenatal exposure.236
Walhovd’s team studied women who underwent opioid agonist
taper and supportive care in a residential facility, finding that
infants born to mothers who detoxified did not show significant
differences in general cognitive function and neuroanatomical
volume as compared to the control group.237 Moreover, none of
the infants born to the mothers who underwent detoxification
experienced NAS.238 Walhovd’s team concluded that
“detoxification in a residential setting is a promising way of
facilitating positive neurodevelopmental outcome of these
children.”239 This particular study, combined with the research
demonstrating successful detoxification with intensive behavioral
therapy, raises substantial policy questions because it
demonstrates a viable treatment alternative that poses less risk
to both the mother and infant.240

234. Fodor et al., supra note 171, at 3; but see Behnke & Smith, supra
note 15, at e1016.
235. Gilardi et al., supra note 196, at 4; Fodor et al. supra note 171, at
3; Nygaard et al., supra note 180, at 333; Byrnes & Vassoler, supra
note 180, at 4-5.
236. Walhovd et al., supra note 180, at 330.
237. Id. at 329.
238. Id. at 330.
239. Id.
240. See id. at 327 (referencing a study that study occurred in Norway,
a country that permits detention of pregnant substance abusing
women in residential treatment as a means to protect the fetus. To
compare in the U.S., only a small minority of states permit civil
commitment for treatment specifically for persons who are engaging
in substance abuse while pregnant.).
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C.
1.

Addressing Gaps in Breastfeeding Guidance

Federal Policy and Clinical Care Recommendations for
Breastfeeding While Enrolled in MAT

According to the World Health Organization (WHO) and
SAMHSA, during the postpartum period women who are stable
and enrolled in MAT should be encouraged to breastfeed their
infant.241 Globally recognized as the ideal method of infant
feeding,242 breastfeeding provides multiple benefits to the infant.
These include optimal nutrition, increased skin to skin contact,
promoting stress reduction in the dyad, and enhanced motherinfant bonding.243 Some research also suggests that breastfeeding
improves symptoms of NAS, such as a reducing the infant’s need
for pharmacological intervention and decreasing the infant’s
length of hospital stay.244
Exposure to opioid agonists during breastfeeding is not
without risks: the AAP found that infants exposed to methadone
or buprenorphine prenatally and through breastmilk exhibited
poor weight gain, lethargy, and respiratory difficulty as compared
to healthy controls.245 Infants exposed to methadone prenatally
and through breastmilk also exhibit more neurocognitive and
motor delays as compared to healthy controls.246 To be sure, these
241. Guidelines for Identification and Management of Substance Use
and Substance Use Disorders in Pregnancy, WHO (Nov. 19, 2014)
[hereinafter WHO], https://www.who.int/publications/i/item/
9789241548731
[https://perma.cc/B7C3-9DC2];
SAMHSA
Treating Pregnant and Parenting Women, supra note 12.
242. American Academy of Pediatrics, Policy Statement: Breastfeeding
and the Use of Human Milk, 129 PEDIATRICS e827, e837 (2012)
[hereinafter AAP Statement on Breastfeeding]; Jill Demirci et al.,
Breastfeeding and Methadone Therapy: The Maternal Experience,
SUBSTANCE ABUSE, 2015, at 1, 8.
243. Demirci et al., supra note 242.
244. Elisha Wachman et al., Revision of Breastfeeding Guidelines in the

Setting of Maternal Opioid Use Disorder: One Institution’s
Experience, 32 J. HUM. LACTATION 382, 382 (2015).
245. Hari C. Sachs et al., Clinical Report: The Transfer of Drugs and

Therapeutics into Human Breastmilk: An Update on Selected
Topics, 132 AM. ACAD. OF PEDIATRICS e796, e800 (2013).
246. Sarah Stretman et al., ABM Clinical Protocol #21: Guidelines for
Breastfeeding and Substance Use or Substance Use Disorder, 10
BREASTFEEDING MED. 135, 136 (2015).
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findings are constrained by the limitation of discerning the
attribution of prenatal versus postpartum impact of methadone
exposure.247 Infants exposed to opioids – whether prescribed or
illicit – demonstrate physical side effects such as hypertonicity
(rigid muscles), excessive movement of their extremities,
irritability, and a disorganized sucking reflex, each of which can
also render breastfeeding difficult.248 The AAP cautions that there
is less information available about buprenorphine during
breastfeeding, stating that animal lactation studies demonstrate
both decreased maternal milk production and decreased viability
of offspring.249 The long-term effects of exposure to opioid agonists
during lactation are unknown.250
Despite potential risks, both federal policy and clinical care
recommendations assure physicians and new mothers that only a
minimal amount of opioids are transferred into breastmilk, and
that maternal use of opioid agonists alone should not alter the
recommendation to breastfeed.251 Nursing professor Jill Demirci
and colleagues lament that stigma, fears, misconception, along
with physician suspicion of the patient’s polysubstance abuse may
lead the physician to discourage breastfeeding.252
SAMHSA provides general recommendations, stating that
breastfeeding is “generally safe” for patients enrolled in MAT but
that a return to substance abuse should trigger several steps.253
First, the provider should assess whether the dose of maintenance
medication is sufficient based on patient report and may need to
increase behavioral counseling.254 If a return to substance abuse
stands as an isolated incident, the provider should not necessarily
counsel the patient to terminate breastfeeding.255 Next, SAMHSA
advises that if substance abuse while enrolled in MAT and
247. Id.
248. Jansson & Velez, supra note 158, at 280.
249. Sachs et al., supra note 245.
250. Id.
251. SAMHSA Tip 43, supra note 21; Demirci et al., supra note 242, at
7; Stretman et al., supra note 246.
252. Demirci et al., supra note 242, at 7.
253. SAMHSA Treating Pregnant and Parenting Women, supra note
12.
254. Id.
255. Id.
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breastfeeding becomes a “common occurrence,” the patient
“should be counseled on her lactation options” and the provider
may consider whether the patient should continue breastfeeding
based on individualized knowledge of the patient.256
The AAP and ACOG suggest that breastfeeding may
continue during substance abuse, provided that certain
benchmarks are met. Both institutions state that maternal
substance abuse is not a categorical contraindication to
breastfeeding, and recommend that mothers can be encouraged
to breastfeed if they are HIV negative, negative for illicit drugs,
and enrolled in a supervised methadone maintenance program.257
The AAP does caution, however, that use of street drugs does
pose risks to an infant’s long term neurobehavioral development
and is contraindicated.258 ACOG also advises that physicians
should have accurate information about the transfer of illicit
substances through breastmilk to adequately counsel nursing
mothers with SUD on the risks and benefits of breastfeeding.259
The Academy of Breastfeeding Medicine (ABM) provides
greater detail within its recommendations. Women with SUD who
are enrolled in MAT and who wish to breastfeed, according to
ABM, should be compliant with substance abuse treatment,
demonstrate abstinence from drug abuse for 90 days prior to
delivery, and should have a negative toxicology screen at
delivery.260 If the patient is not engaged in treatment or has no
plans to obtain treatment, has positive toxicology screens at
birth, or relapses to illegal substance abuse, ABM states that
patients should be counseled not to breastfeed.261 This is
specifically because there is an absence of pharmacokinetic data
to establish the presence or concentration of the illicit substance
or its metabolites in human milk and its effect on the infant.262
Finally, ABM warns: “[W]omen using illicit substances in the
postnatal period may exhibit impaired judgment and secondary
behavioral changes that may interfere with the ability of the
256. Id.
257. AAP Statement on Breastfeeding, supra note 242, at e833.
258. Id.; ACOG, supra note 12.
259. Id.
260. Stretman et al., supra note 246, at 138.
261. Id. at 139.
262. Id.
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mother to care for her infant or to breastfeed adequately.”263 Such
a detailed recommendation, recognition that continued
breastfeeding may not be a safe option for the infant, and
acknowledgement that substance abuse impacts maternal
behavior should be recognized as the standard of care in both
clinical interactions and public health discussions.
2. Clinical Considerations for Providers Counseling Women with
SUD on Breastfeeding

Integrating statistics relating to patients who either relapse
or continue substance abuse raises the question of how physicians
should counsel breastfeeding women who may be enrolled in
MAT. Federal policy, set forth by SAMHSA, provides that
generalized recommendations may be insufficient to communicate
to physicians the significant impact of ongoing substance abuse:
the high rates at which pregnant patients enrolled in MAT
continue abusing illicit opioids (49-81%), abuse the prescribed
opioid, and/or engage in ongoing polysubstance abuse with other
substances such as cocaine or marijuana (48-81%).264 These
statistics must be interpreted in conjunction with the severity of
consequences that may follow infant ingestion of breastmilk
containing multiple intoxicating substances. All providers on the
care team, including physicians, nurses, and lactation consultants
should communicate not only the benefits of breastfeeding, but
also the challenges and serious risks of breastfeeding while
abusing prescribed medications or illicit drugs.
Despite Demirci and colleagues’ perception that unwarranted
stigma and misconceptions underlie providers’ subtle
discouragement against breastfeeding,265 these statistics provide a
more nuanced view.
First, despite the lack of well-controlled data on side effects
to the infant from breastmilk exposure to illicit substances,
observational data does exist and shows adverse effects from
263. Id.
264. SAMHSA Treating Pregnant and Parenting Women, supra note
12; see also Federal Guidelines for Opioid Treatment Programs,
SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN. (Jan. 2015),
https://store.samhsa.gov/sites/default/files/d7/priv/pep15fedguideotp.pdf [https://perma.cc/VN4P-E3DM].
265. Demirci et al., supra note 242.
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certain drug categories.266 These categories range from infant
agitation, lethargy, apnea, central nervous system depression,
infant intoxication, and infant death.267 Based on the above
statistics, adverse effects to the infant are not merely a remote
possibility, but probable. Accordingly, ABM’s statement
cautioning that patients who relapse should be counseled not to
breastfeed must be explicitly made clear by physicians to other
providers in the care team and to the patient.
Second, physicians Jansson and Velez assert that maternal
self-reporting of substance abuse is “markedly inaccurate” due to
underreporting.268 The high rates of maternal substance abuse
combined with underreporting suggest a high probability that
nursing mothers enrolled in MAT continue to engage in substance
abuse. Alternatively, nursing mothers struggling with SUD with
no intention of stopping may act strategically to avoid detection
by their providers.269
To illustrate: in 2014, Stephanie Greene, a nursing mother of
four, was numerous prescribed opioids, including morphine and
opioid patches.270 Greene was prescribed opioids for her
fibromyalgia and pain following a motor vehicle accident.
Allegedly struggling with addiction, she lost her nursing license
for trying to illegally obtain drugs and refusing drug testing.271
266. Jansson & Velez, supra note 158, at 278.
267. Id.
268. Id. at 280.
269. South Carolina Mom Gets 20 Years in Breastfeeding Overdose, FOX
NEWS (Apr. 5, 2014), https://www.foxnews.com/us/southcarolina-mom-gets-20-years-in-breast-feeding-overdose
[https://
perma.cc/2RB6-XY75] (stating that Stephanie Greene, a former
nurse with four children, lost her nursing license for trying to
illegally obtain drugs and refusing drug testing. Greene acted
strategically throughout her pregnancy; concealing her pregnancy
from her primary care provider so that she could continue obtaining
prescribed opioids—morphine and opioid patches—while
concealing information about her drug use to her obstetrician).
270. Id.; Mother Gets 20 Years for Infant’s Death Due to Negligent
Breastfeeding, REUTERS (Apr. 10, 2014), https://www.rt.com/
usa/mother-20-prison-negligent-breastfeeding-524/
[https://
perma.cc/J3B6-6KP3].
271. Mother Gets 20 Years for Infant’s Death Due to Negligent
Breastfeeding, supra note 270; South Carolina Mom Gets 20 Years
in Breastfeeding Overdose, supra note 269.
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Greene intentionally hid her pregnancy from her primary care
provider so she could continue obtaining prescribed opioids
(morphine and opioid patches) while concealing information
about her drug abuse to her obstetrician.272 Greene’s daughter,
Alexis, died from acute morphine intoxication transferred by
Greene’s breastmilk.273 According to the coroner’s report, there
was almost 50 times greater morphine in Alexis’s system than
would be expected from prescribed pain medication, along with
three additional drugs.274 Greene’s circumstances demonstrate
that patients taking a prescribed medication may struggle with
addiction to that medication, take measures to avoid discovery of
the addiction, and may abuse the medication. Moreover, abusing
the medication can result in the transfer of lethal amounts of that
medication in breastmilk.275
Similarly, Amoret Powell, a mother to three children,
employed a similar strategy in efforts to continue abusing drugs
while breastfeeding.276 Struggling with SUD, Powell had been
prescribed methadone but had relapsed back to injecting heroin
following the birth of her third child, Eve.277 Powell told
investigators that she would wait two hours after injecting heroin
to pump breastmilk, then breastfeed Eve.278 Eve also died from
acute drug toxicity transferred by breastmilk from her mother.279
Despite impairment from the influence of substances,
Greene’s and Powell’s cases illustrate that pregnant and
272. Id.
273. Woman Given 20 Years for Killing Daughter With Morphine in
GUARDIAN
(Apr.
4,
2014),
https://www.
Breastmilk,
theguardian.com/world/2014/apr/04/woman-20-years-killingdaughter-morphine-breast-milk [https://perma.cc/4FWH-ERFB].
274. Mother Gets 20 Years for Infant’s Death Due to Negligent
Breastfeeding, supra note 270.
275. Id. Kounang, supra note 1 (noting that there is no clear proof that
the small amount of drugs that exist in breast milk are actually
enough to kill a baby).
276. Associated Press, Drug-Tainted Breast Milk Leads to Charge of
Murder, N.Y. TIMES (Aug. 3, 1997), https://www.nytimes.com/
1997/08/03/us/drug-tainted-breast-milk-leads-to-charge-ofmurder.html [https://perma.cc/W2DA-B5QP].
277. Id.
278. Id.
279. Id.
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parenting women with SUD still exhibit planning and reason,
seemingly focused on how to conceal their drug abuse from
providers.280 Patients taking prescribed opioids while
breastfeeding may act intentionally to conceal their addiction,
with no intention of stopping substance abuse. Further, they may
continue substance abuse despite receiving MAT. At a minimum,
this triggers a duty for providers to counsel their patients about
the serious risks of breastfeeding following relapse or during
ongoing substance abuse and explicitly warn the patient of risks
not only to herself, but also the risk of infant intoxication and
death that triggers criminal liability.281
Third, Demirci and colleagues’ semi-structured interviews
and focus groups with women enrolled in MAT revealed that
multiple women expressed apprehension related to nursing, while
in MAT, including concerns about the transfer of prescribed
medication and that the infant could become “high” or
overdose.282 This suggests that nursing mothers acknowledge that
substances they consume are transferred through their breastmilk
to their infant. Physicians should respond to these reasonable
anxieties by explaining the risk-benefit calculation behind MAT
while nursing – acknowledging that, while opioid agonists used in
MAT may present risk to the infant, this is weighed against the
benefit of the mother’s recovery.283 Notably, this calculation
presumes that pregnant, parenting, and nursing mothers enrolled
in MAT are actively engaged in recovery and have discontinued
280. Rebecca Stone, Pregnant Women and Substance Use: Fear, Stigma,
and Barriers to Care, 3 HEALTH & JUST. 1, 6-7 (2015).
281. See, e.g., Pregnancy and Substance Abuse: A Harm Reduction
Toolkit, NAT’L HARM REDUCTION COALITION (Sept. 2020), https://
harmreduction.org/issues/pregnancy-and-substance-use-a-harmreduction-toolkit/ [ttps://perma.cc/VJ9X-XWZN].
282. Demirci et al., supra note 242, at 3-4; see also Doyle Murphy,
California Baby Dies After Drinking Mother’s Drug-Laced Milk,
N.Y.
DAILY
NEWS
(Sept.
13,
2013),
https://www.
nydailynews.com/news/national/cops-baby-killed-mom-druglaced-milk-article-1.1443412
[https://perma.cc/4WCF-KUR4]
(describing the case of Sarah Stevens, who abused Xanax, illicit
(prescribed) methadone, and Opana while breastfeeding, which
transferred a fatal cocktail of drug into the system of her son, Ryder
Salmen, resulting in his death).
283. See discussion supra notes 50-63 and accompanying text.
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substance abuse. It must change when women continue substance
abuse in addition to receiving opioid agonists through MAT. In
that circumstance, the physician should not only counsel the
patient to stop breastfeeding, but must re-evaluate the patient’s
treatment for SUD and consider whether it is a sufficient
intervention.
D.
1.

Best Practices for Informed Consent

Ethical and Legal Considerations for Informed Consent to
SUD Treatment

After evaluating current research, it is apparent that the
standard of care for the informed consent process must be
modified. Both the legal doctrine of informed consent and ethicist
Tom Beauchamp’s framework of medical ethics principles
illustrate that informed consent constitutes more than
acquiescence – cursory agreement to a physician’s
recommendation for a particular course of treatment –and instead
requires disclosure, comprehension, voluntariness, competence,
and consent.284 Providing accurate and balanced information
relating to risks, benefits, and alternatives promotes the values of
patient autonomy, dignity, and trust in the medical profession.
Acting as fiduciaries, physicians should interpret the complexities
of research-supported benefits and risks of different treatment
options. Within this specific context, informed consent promotes
optimal maternal decision-making by allowing the mother to assess
risks and benefits for herself and her infant.285
If physicians omit relevant information or do not provide
sufficient information to satisfy the element of disclosure, this not
only exposes the patient to risks of treatment for which she did
not actually consent, but also raises issues of potential liability
for the physician.286 Some courts, recognizing a physician’s duty
to guard the patient’s interest, have held that physicians treating
persons with addiction are held to a heightened standard because
patients struggling with addiction may have diminished decision284. Tom L. Beauchamp, Informed Consent: Its History, Meaning, and
Present Challenges, 20 CAMBRIDGE Q. HEALTHCARE ETHICS 515,
518-19 (2011).
285. WHO, supra note 241, at 7.
286. See e.g., Jennifer Grauberger et al., Allegations of Failure to Obtain
Informed Consent in Spinal Surgery Medical Malpractice Claims,
JAMA SURGERY, 2017, at 1, 5-6.
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making capacity when they act contrary to their own interests to
obtain and ingest more drugs.287 The duty of informed consent,
as both a legal and ethical matter, then becomes a consideration
of how to provide treatment that enables the patient to recover
and restores her to a state of autonomy.288
Patient autonomy and choice are imperative to recovery, and
patients should be provided with factually-correct information.289
SAMHSA recommends that patient education and treatment
decisions should reflect shared decision-making, a respect for the
patient’s goals and preferences, and should address balancing the
treatment needs of the pregnant or parenting patient with the
impact of treatment to the fetus or infant.290
2.

Specific Recommendations for Providers Discussing Treatment
Options with Pregnant and Parenting Women with SUD

As a preliminary matter, conversations relating to treatment
options should acknowledge that most research conducted on
prenatal and parenting opioid addiction pertains to women
abusing heroin, which is a clinically distinct patient population.291

287. See Procaccini v. Lawrence and Memorial Hospital Inc., 175 Conn.
App. 682 (Conn. App. Ct. 2017) (involving a deceased patient who
previously received treatment from an Opioid Treatment Provider
wherein she received methadone. The Opioid Treatment Provider
discharged the patient, and one week after the patient’s last dose
of prescribed methadone, the patient obtained illicit methadone
and
overdosed,
dying
of
respiratory
distress—despite
administration of naloxone and admission for emergency care); see
also Piscitelli v. Hospital Authority of Valdosta, 691 S.E.2d 616
(11th Cir. 2010) (involving a deceased patient who was enrolled in
a drug and alcohol abuse treatment facility and died during the
induction period four days into the treatment—a medical examiner
testified that methadone toxicity was the cause of death in the
patient).
288. See JONATHAN PUGH, AUTONOMY,
CONTEMPORARY BIOETHICS 155-57 (2020).

RATIONALITY,

AND

289. Lauren M. Wancata & Daniel B. Hinshaw, Rethinking Autonomy:

Decision Making Between Patient and Surgeon in Advanced
Illnesses, 4 ANNALS TRANSLATIONAL MED. 77, 77 (2016).
290. SAMHSA Treating Pregnant and Parenting Women, supra note
12; SAMHSA Collaborative Approach, supra note 19.
291. ACOG, supra note 12; see also Andrew Kolodny et al., The

Prescription Opioid and Heroin Crisis: A Public Health Approach
to an Epidemic of Addition, 36 ANN. REV. PUB. HEALTH 559, 560
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As addiction physician Andrew Kolodny points out—not all
pregnant or parenting women with opioid dependence have an
addiction, but instead may seek assistance managing the physical
and psychological symptoms of withdrawal from dependence on a
prescribed opioid.292
The current evidence for either population – women with
opioid dependence, or women with OUD struggling with
addiction – does not suggest that withdrawal during pregnancy is
extremely dangerous to the fetus or leads to pregnancy loss or
preterm labor.293 Physician conversations with patients should not
further promote this warning as a risk when it stands contrary to
current evidence. Instead, the most recent evidence demonstrates
that medically supervised detoxification is not only a safe clinical
option, but that a majority of women, independent of length of
addiction, can successfully undergo detoxification with supportive
therapy without relapse.294 Multiple studies suggest that women
should be offered the option to detoxify, and it is reasonable that
adequate disclosure would include the probability of success and
the key role of supportive behavioral treatment as a variable that
promotes successful detoxification.295 Although some physicians
maintain that detoxification causes fetal distress, there is limited
evidence to support this claim;296 as compared to MAT,
supervised detoxification does not pose a distinct set of risks to
fetal physical and neurological development.297
Compounding the recommendation against detoxification,
federal policy and clinical recommendations currently
demonstrate a marked bias toward directing pregnant patients to
accept MAT. Indeed, a sample informed consent form published
(2015) (describing the link between the increase in prescriptions for
opioids and rising rates of overdose); Drabiak, supra note 14, at 32.
292. Drabiak, supra note 14, at 31.
293. See supra notes 106-7 and accompanying text; but see Mishka
Terplan, et al., Opioid Detoxification During Pregnancy: A
Systematic Review, 131 OBSTETRICS & GYNECOLOGY 803, 804
(2018).
294. See supra Part II(A).
295. Stone supra note 281, at 13.
296. See supra Part II(A).
297. Editorial Staff, Detoxing While Pregnant, AM. ADDICTION CTRS.,
https://americanaddictioncenters.org/drug-detox/pregnant
[https://perma.cc/B6MJ-F7JB] (last updated Feb. 25, 2022).
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by SAMSHA instructs providers to use the informed consent
process to counsel their patients to understand that
pharmacotherapy will help them.298 SAMHSA depicts the patient
education process as a time to discuss the risks of untreated
addiction, comparing these risks against the risks of benefit of
MAT.299 But this discussion should acknowledge that the
presented options are not a binary of MAT versus no treatment.
Instead, physicians should counsel patients that treatment may
include MAT or other options, such as supervised tapering for
opioid dependence or supervised detoxification with behavioral
treatment for addiction. Sample patient brochures downplay
adverse effects and risks indicated in FDA product information
and current literature.300 These brochures inform pregnant and
parenting patients that MAT is safe and normalizes patient
function, but this simplification omits significant aspects of
clinically relevant information.301 Conversations between provider
and patient should not only include potential benefits of MAT,
but also a discussion of the complexities of risks involved. These
risks may include physical side effects such as: headaches,
depression, and endocrine dysfunction; neurological effects on
cognition, memory, and executive function; and risks associated
with somnolence and impairment.302 Each of these possible side
effects not only affects the woman’s quality of life and recovery,
but directly impacts the woman’s ability to conduct daily life
activities, including her ability to safely parent.
Providers should further communicate the limitations of
MAT, and state that while it may work for some patients who
tolerate its side effects, it may not necessarily block the craving
for illicit substances and patients may still feel a compulsion to

298. SAMHSA Treating Pregnant and Parenting Women, supra note
12.
299. Id.
300. Id.
301. Id.
302. Theresa Parisi, Medication-Assisted Treatment for Opioid Use
Disorders, ADDICTION CTR. (Mar. 20, 2019) https://www.
addictioncenter.com/community/medication-assisted-treatmentfor-opioid-use-disorders/ [https://perma.cc/PWN5-DK59]; see also
Sheridan et al., supra note 162.
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engage in substance abuse.303 Importantly, providers should
communicate to patients that they may experience impairment
on prescribed doses of opioid agonists.304 Based on high rates of
continued substance abuse among general patient populations
and pregnant and parenting women who are enrolled in MAT,
providers should counsel women on the risks to the fetus or infant
associated with continued substance abuse.305
Acting as decision-makers on behalf of their fetus and infant,
pregnant and parenting patients require accurate information on
the benefits and risks of MAT on fetal and infant development.
Although clinical literature acknowledges the risk of NAS to
infants prenatally-exposed to opioid agonists, federal policy,
clinical guidelines, and physician conversations pertaining to
potential risks to the fetus and infant require modification to
comport with accurate disclosure based on available evidence.
SAMHSA and ACOG’s statements asserting that there is “no
evidence” that MAT is harmful to the developing infant and
concerns that MAT increases risk of adverse developmental
outcomes are “unscientific” stand contrary to numerous studies.306
Multiple studies demonstrate physical risks of prenatal opioid
exposure to the infant, including: an increased risk of low birth
weight, decreased brain volume, decreased body length; and risk
of morbidities including: cardiac malformation, respiratory
insufficiency, visual anomalies, preterm birth, and SIDS.307
303. New Choices Treatment Centers Admin, Medication-Assisted
Treatment: Pros and Cons of MAT for Recovery, NEW CHOICES
TREATMENT CTRS. (July 10, 2020), https://newchoicestc.com/
blog/medication-assisted-treatment-pros-and-cons-of-mat-forrecovery-nc/ [https://perma.cc/G8ED-BVB8]; see also The Role
(and Limitations) of Medication Assisted Treatment (MAT),
LIGHTHOUSE RECOVERY TEX. (Dec. 26, 2020), https://
lighthouserecoverytx.com/the-role-and-limitations-of-medicationassisted-treatment-mat/ [https://perma.cc/RA56-V5EE].
304. Opioid Agonist Therapy, CTR. FOR ADDICTION & MENTAL HEALTH
(2016),
https://www.camh.ca/-/media/files/oat-info-forclients.pdf [https://perma.cc/3UCR-S59G].
305. See SAMHSA Treating Pregnant and Parenting Women, supra
note 12; see also Jean Ko, What Can We Do About Opioid Use
Disorder in Pregnancy, MEDSCAPE (Jan. 28, 2019),
https://www.medscape.com/viewarticle/907407?src=par_cdc_st
m_mscpedt&faf=1 [https://perma.cc/U4Z9-ZPFR].
306. See supra notes 95-98 and accompanying text.
307. See supra notes 202-218 and accompanying text.
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Additionally, federal policy, clinical guidelines, and physicians
should disclose the neurological risks of MAT, including: an
adverse effect on neuroanatomical volume, neurological
development, cognition, memory and executive function.308
Finally, all postpartum providers - including physicians,
nurses, and lactation consultants - should become familiar with
the specific guidance set forth by ABM for how to address women
with SUD. This recommendation remains relevant even when the
patient is taking an opioid agonist as prescribed or pursuant to
MAT or when breastfeeding is recommended or contraindicated.
While providers should encourage safe breastfeeding practices,
they should also counsel their patients about the serious risks of
breastfeeding following relapse or during ongoing substance
abuse. Providers should explicitly warn the patient of the risks of
intoxication and death, both to herself and her infant, and explain
how that could expose her to criminal liability.

IV. HOW THE LAW CLASSIFIES MATERNAL SUBSTANCE
ABUSE
This section explores how the law addresses the problem of
prenatal and parenting substance abuse, explaining why
presenting a binary solution as either offering treatment or
punishment is misleading and misses key nuances. Next, this
section will address the impact of prenatal and parenting
substance abuse on parental conduct and the intersection in the
civil law context. It will also provide an overview of state laws
that define prenatal and parenting substance abuse as civil child
neglect or abuse and discuss corresponding state interventions
through CPS. To address the problem of pregnant and parenting
women who leave treatment or refuse treatment despite ongoing
substance abuse, this section will describe how a minority of
states have laws that permit civil commitment to facilitate
treatment for persons with habitual and uncontrollable substance
abuse. Finally, this section will describe the intersection of the
criminal justice system with pregnant and parenting substance
abuse and provide an analysis of key cases that involve death or
injury to infants resulting from maternal substance abuse.
308. Margaret A. Maglione et al., Effects of Medication Assisted

Treatment (MAT) for Opioid Use Disorder on Functional
Outcomes: A Systematic Review, 89 J. SUBSTANCE ABUSE
TREATMENT 28, 34 (2018).
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A.

False Binary: Treatment v. Punitive Measures

Clinicians, public health professionals, policymakers, and
legislators hold a range of opinions on how the law should address
maternal substance abuse. Current debates present responses to
maternal substance abuse as a binary—either offer treatment or
favor punitive enforcement measures. The latter frames prenatal
substance abuse simplistically as a problem
of insufficient
treatment facilities or a scarcity of programs designed for
pregnant and parenting women.309 ACOG asserts punitive
enforcement policies are ineffective, and the AAP calls for a public
health response rather than a punitive response, stating that
prosecuting pregnant women for drug abuse has no proven benefit
to maternal or infant health, may lead the patient to avoid
prenatal care, and may decrease the patient’s likelihood of
engaging in treatment.310 Similarly, the American Public Health
Association (APHA) recommends that no punitive measures be
taken against a pregnant woman for prenatal substance abuse
“when no other illegal acts, including drug-related offenses have
been committed.”311 ACOG asserts that civil reporting statutes
designed to alert CPS of maternal drug abuse are undesirable
policy interventions and calls for the retraction of “punitive
legislation.”312 ACOG and AAP both disfavor civil mandatoryreporting statutes that would trigger a CPS investigation for
prenatal substance abuse, asserting that this will cause patients
with SUD to avoid prenatal care.313
Multiple stakeholders including Amnesty International and
National Advocates for Pregnant Women frame both criminal
309. See Wendy K. Mariner et al., Pregnancy, Drugs, and the Perils of
Prosecution, 9 CRIM. JUST. ETHICS 30, 36-37 (1990); see also BISHOP
ET AL., supra note 17, at 4-5; ACOG, supra note 12; Patrick &
Schiff, supra note 12.
310. ACOG, supra note 12; Patrick & Schiff, supra note 12, at 1-3.
311. Medical and Public Health Statements Addressing Prosecution and
Punishment of Pregnant Women, NAT’L ADVOCS. PREGNANT
WOMEN, https://www.nationaladvocatesforpregnantwomen.org/
wp-content/uploads/2019/02/Health20Statements20re.20Punitive
20Policies20NAPW202015.pdf
[https://perma.cc/T2DQ-4MBK]
(last visited Mar. 7, 2021).
312. ACOG, supra note 12.
313. Id.; Patrick & Schiff, supra note 12, at 3; Paltrow, supra note 181,
at 464.
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and civil state law interventions aimed at addressing prenatal
substance abuse as actions that “criminalize pregnancy”314 and
discriminate against pregnant women.315 These stakeholders
assert that both criminal and civil interventions place blame upon
women for conduct they do not freely choose;316 that substance
abuse during pregnancy is rarely voluntary; and that women may
not be able to stop drug abuse.317 As described supra in Section
III B, some stakeholders further argue that there is insufficient
evidence to even establish that prenatal or parenting substance
abuse causes harm to the fetus or infant.318 Extending this
premise, Lollar maintains that laws aimed at intervening against
pregnant and parenting women’s abuse of substances are merely
tied to a subjective negative connotation associated with drugs in
our society and moral judgments against mothers who use those
drugs.319
However, as former State’s Attorney Paul Logli has pointed
out, there is almost a universal misconception that criminal
prosecution for substance abuse related-offenses leads to punitive
measures such as incarceration.320 Prosecuting women who engage
in habitual substance abuse during pregnancy does not equate to
“stripping a woman of her rights, denying her legal
representation, locking her up, and calling her a criminal.”321
Instead, it may lead to a period of court supervision to ensure
that the woman stops drug abuse if she can; alternatively, the
supervision may facilitate her entering treatment and may involve
CPS oversight to assess the safety of her home environment,

314. AMNESTY INT’L, CRIMINALIZING PREGNANCY: POLICING PREGNANT
WOMEN WHO USE DRUGS IN THE USA 47 (2017).
315. Id. at 10; Patrick & Schiff, supra note 12, at 3.
316. AMNESTY INT’L, supra note 314, at 25.
317. Paltrow, supra note 181, at 475-78.
318. See supra Part III (B).
319. Lollar, supra note 181, at 980-81.
320. Paul Logli, The Prosecutor’s Role in Solving the Problems of
Prenatal Drug Use and Substance Abused Children, 43 HASTINGS
L.J. 559, 561-62 (1992).
321. Jessica Boudreaux & John Thompson, Maternal-Fetal Rights and
Substance Abuse: Gestation Without Representation, 43 J. AM.
ACAD. PSYCHIATRY & L. 137, 140 (2015).
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particularly if there are other children in the home.322 Some legal
experts such as Logli frame prosecution as a lever of
accountability to foster rehabilitation by providing treatment
referrals, periodic drug testing to ensure compliance, and
assistance such as parenting classes.323 In many courts, the system
functions as a diversion program or offers deferred prosecution
(no prosecution and no sentence as long as the defendant follows
the court orders relating to treatment).324
These positions raise the question of how the law should
approach pregnant and parenting women who engage in
substance abuse while enrolled in, leave, or refuse treatment.
Despite ACOG and AAP’s stance against civil reporting statutes,
many states do consider maternal substance abuse civil child
abuse.325 However, even if CPS intervenes to facilitate treatment,
this may be insufficient to prevent harm if the mother continues
substance abuse in treatment or does not comply with CPS’s
order to attend treatment. Should the law instead permit civil
commitment for pregnant women who habitually abuse
substances and refuse treatment?
Finally, how should the law address egregious acts by
pregnant and parenting women that are connected to their
substance abuse and result in harm or death to infants and
children?
B.

Maternal Substance Abuse: Civil Child Abuse and Neglect
Laws

1.

The Impact of Maternal Substance Abuse on Parenting

Some legal activists and scholars deny that maternal
substance abuse adversely impacts the infant or even exerts an
effect upon mothers’ parenting, asserting that CPS interventions
function to penalize parents.326 Paltrow maintains there is “no
322. See Logli, supra note 320, at 562-66.
323. Id.
324. Id.
325. Substance Use During Pregnancy, GUTTMACHER INST., (Jan. 1,
2022) [hereinafter GUTTMACHER], https://www.guttmacher.org/
state-policy/explore/substance-use-during-pregnancy#:~:text=
24%20states%20and%20the%20District,it%20grounds%20for%20ci
vil%20commitment [https://perma.cc/E9R6-VES9].
326. Paltrow, supra note 181, at 474; Martin, supra note 186.
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significant difference” between addicted and non-addicted
mothers, arguing that it is a “misconception” that prenatal
substance abuse indicates neglect or abuse after birth.327 Child
welfare reporting statistics, crime reports, and disturbing media
cases do not support such assertions.328 While some CPS
investigations undoubtedly sweep in parents without merit or
involve mothers who recovered from substance abuse,329 this is
neither the intention nor purpose of CPS.330
Current research instead suggests a significant correlation
between habitual parental substance abuse and child neglect,
with one study finding a correlation as high as eighty-three
percent.331 Notably, discussion of parental substance abuse here
involves habitual, chronic, or excessive substance abuse that
implicates impairment and ability to function. Parental
substance abuse can impact parenting in a variety of ways—
increasing parental forgetfulness, increasing somnolence or erratic
behavior, forgoing purchasing food and instead using household
finances to buy drugs.332 Or further, leaving children
unattended,333 exposing children to crimes related to substance
abuse such as theft, prostitution, and drug dealing, and living in
a home environment in which controlled substances are within
327. Paltrow, supra note 181, at 480-81.
328. See, e.g., Mohsen Hosseinbor, Family Functioning of Addicted and
Non-Addicted Individuals: A Comparative Study, 1 INTER’L J.
HIGH RISK BEHAVIORS & ADDICTION 109, 109 (2012).
329. Bruce Vielmetti, Pregnant Woman Fights Wisconsin’s Fetal
Protection Law, MILWAUKEE J. SENTINEL (Oct. 24, 2013),
http://archive.jsonline.com/news/crime/pregnant-woman-fightswisconsins-fetal-protection-law-b99127289z1-229077121.html/
[https://perma.cc/B72Z-ZW67] (describing the case of Alicia
Beltran who asserted she had recovered from addiction and did not
want to need treatment including an order to begin MAT).
330. See How to Report Child Abuse and Neglect, Child Welfare
https://www.childwelfare.gov/topics/
Information
Gateway,
responding/reporting/how/ [https://perma.cc/4B97-A7X4] (last
visited Feb. 8, 2022).
331. Logli, supra note 320, at 561.
332. See Arlene Levinson, Crack Mom Does Time as Her Children Grow,
SOUTH COAST TODAY (Apr. 26, 1998), https://www.
southcoasttoday.com/article/19980426/News/304269949
[https://perma.cc/C5D7-A7DL].
333. Id.
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children’s reach.334 One report examining substance-exposed
infants at birth found that 61.2% involved subsequent
investigations opened by CPS to assess claims of child abuse or
neglect, 45.4% of which claims were substantiated by CPS before
the child’s first birthday.335
In fact, a variety of media reports have raised the question of
whether CPS sufficiently intervenes, asserting that, in the cases
reported upon, CPS should have been more aggressive
investigating the safety of the home environment.336 In one
investigation, Reuters identified 110 cases of infants and toddlers
whose mothers abused opioids during pregnancy and died
preventable deaths, including forty children who suffocated and
thirteen who swallowed toxic doses of controlled substances.337 In
approximately seventy-five percent of those cases, the mother was
implicated in causing the death of her child, but most women
were sent home from the hospital after giving birth to a
substance-exposed infant without the hospital ever notifying
CPS.338
In one case, Sarah Stephens abused multiple drugs, including
methadone, while breastfeeding her son Ryder.339 When Ryder

334. Id.
335. John J. Prindle et al., Prenatal Substance Exposure Diagnosed at
Birth and Infant Involvement with Child Protective Services, 76
CHILD ABUSE & NEGLECT 75, 79 (2018).
336. Jenifer McKim, Explosion of Drug-Dependent Infants Reveals
Weakness of Mass. Child Protection, GBH NEWS (Mar. 30, 2014),
https://www.necir.org/2014/03/30/explosion- of-drug-dependentinfants-reveals-weakness-in-mass-child-protection/
[https://
perma.cc/K4VX-KPUC]; Wilson & Shiffman, Newborns Die After

Being Sent Home With Mothers Struggling To Kick Drug
Addictions, supra note 159.
337. Wilson & Shiffman, Newborns Die After Being Sent Home With
Mothers Struggling To Kick Drug Addictions, supra note 159.
338. Id.
339. Doyle Murphy, California Baby Dies After Drinking Mother’s Drug
Laced Milk, N.Y. DAILY NEWS (Sept. 2, 2013), https://
www.nydailynews.com/news/national/cops-baby-killed-momdrug-laced-milk-article-1.1443412 [https://perma.ccYF6C-64VK];
Anthony Bond, Pictured: The Eight-Month-Old Baby Who Died

From a Cockail of Methadone and Xanax in Mother’s Breast Milk
and Now She Faces Murder Charges, DAILY MAIL (Sept. 2, 2013),
https://www.dailymail.co.uk/news/article-2408718/Ryder-
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was four months old, he was admitted to the emergency
department for an accidental overdose from drugs transferred by
Stephens via breastmilk.340 At that time, the hospital notified
CPS to initiate an investigation; however CPS neglected to act
for three months, releasing Ryder into Stephens’ custody only
with the warning to discontinue breastfeeding, and then
determined there was “low risk of future mistreatment.”341 Months
later, police called CPS again when Stephens ran her vehicle off
road with Ryder in the backseat; CPS did not complete any other
risk assessment or conduct further investigation.342 Less than a
month later, Ryder died from acute drug intoxication by ingesting
Xanax, Opana, and methadone-laced breastmilk from Stephens.
343
This raises questions about the timeliness and responsiveness
of CPS in assessing and remediating serious safety concerns.
As described in the cases of Stephanie Greene and Amoret
Powell, pregnant and parenting women who engage in substance
abuse may alternate between periods of impairment and
carelessness and periods of demonstrated planning designed to
avoid detection and fuel their addiction.344 Media reports have
uncovered the corresponding impact on safety and related
accidents, such as when maternal somnolence results in a mother
falling asleep and smothering her infant,345 when Amanda
McKenzie fell asleep while bathing her infant, Liam, causing him
to drown,346 or cases like Samantha Jones’ and others, when
parents become unconscious in a vehicle with a child in the
backseat.347 Impairment may also contribute to parents leaving
Salmen-months-died-cocktail-drugs-mothers-breast-milk.html
[https://perma.cc/YF6C-64VK].
340. Bond, supra note 339.
341. Id.
342. Id.
343. Id.
344. See Part III(b).
345. Wilson, A Hospital Fails to Test for Drugs; A Day Later, A
Newborn is Dead, supra note 159; Wilson & Shiffman, Newborns

Die After Being Sent Home with Mothers Struggling To Kick Drug
Addictions, supra note 159.
346. Wilson, As Social Services Stand Back, A Mother and Her Baby
Fall ‘Through the Canyon into Hell’, supra note 159.
347. Veazey, supra note 156; Svab, supra note 177.
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controlled substances in areas that children can access. In one
case, Penny Cormani’s parents actively abused heroin in their
home, leaving heroin and drug paraphernalia such as burnt foil
and straws in multiple places around the home.348 Thirteenmonth-old Penny accidentally ingested her parents’ heroin and
died from acute heroin intoxication.349
Notably, several cases raise the possibility that the mothers
themselves would have liked to discontinue taking prescribed
opioid agonists but struggled with dependence on the prescribed
medication,350 or alternatively, were unaware that taking opioid
agonist medications along with postpartum pain relief
medications as prescribed could result in infant intoxication and
death.351 Several mothers expressly stated that they wished CPS
would have intervened, or that they would have welcomed help.352
Critically, the population of women experiencing problems that
involve substance abuse, impairment, and accidents that result in
the infant’s death includes women who are enrolled in MAT.353
One investigation examined a Bradenton, Florida methadone
clinic where, in the span of six months, four infants born
dependent on substances whose mothers were enrolled in MAT
died accidental deaths.354 Cases such as these highlight the
importance of solutions to address pregnant and parenting
substance abuse, even when the mother is already enrolled in
MAT.
348. McKenzie Romero, Lehi Mother Sent to Prison for Baby’s Heroin
Overdose, DESERET NEWS (Mar. 2, 2017), https://www.
deseretnews.com/article/865674722/Lehi-mother-sent-to-prisonfor-babys-heroin-overdose.html [https://perma.cc/8YVF-CFFH];
Julie Turkewitz, ‘The Pills Are Everywhere’: How the Opioid Crisis
Claims Its Youngest Victims, N.Y. TIMES (Sept. 20, 2017),
https://www.nytimes.com/2017/09/20/us/opioid-deathschildren.html [https://perma.cc/5FSE-3AXQ].
349. Romero, supra note 348; Turkewitz, supra note 348.
350. Wilson & Shiffman, Newborns Die After Being Sent Home with
Mothers Struggling To Kick Drug Addictions, supra note 160.
351. Id.
352. Id.
353. Duff Wilson, Infant Deaths Prompt Changes at Methadone Clinic,
REUTERS
(Dec.
7,
2015),
http://news.trust.org//item/
20151207221247-lr4c5 [https://perma.cc/M4JY-DMNJ].
354. Id.
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Finally, the most egregious cases demonstrate unspeakable
cruelty toward children. These cases raise questions about
society’s role in protecting children from a small subset of parents
who fail to act in their children’s best interest, deviating far away
from a minimum standard of care. Cases range from reckless
indifference, such as Mya Barry’s parents who tainted her baby
bottles with heroin, causing her overdose,355 to utter disregard,
such as a mother who gave her infant Tylenol and methadone to
keep her infant quiet.356 In one of the most gruesome cases,
Lyndsey Fiddler engaged in ongoing substance abuse, became
intoxicated, started a load of laundry and dumped her infant
Maggie May into the washing machine where she violently
drowned and died.357 Alarmingly, CPS had received five reports
alleging that Fiddler neglected or abused her three children,
including a report when Maggie May was born.358 CPS, however,
determined that Fiddler’s children were safe and that Fiddler
could work on parenting services.359
To be sure, in practice, CPS interventions may include
examples of overbroad investigations or unwarranted
intrusions.360 Yet, where maternal substance abuse and substancedependent infants are involved, these cases demonstrate the
breadth of impact and severity of consequences when CPS does
not intervene in a timely and responsive manner, or fails to
intervene at all.
2.

Maternal Substance Abuse May Constitute Civil Child Abuse
or Neglect

Twenty-three states and the District of Columbia classify
prenatal substance abuse as civil child abuse, and twenty-four
states require healthcare providers to report prenatal substance

355. McKim, supra note 336.
356. Wilson & Shiffman, Newborns Die After Being Sent Home with
Mothers Struggling to Kick Drug Addictions, supra note 160.
357. Id.
358. Id.
359. Id.
360. See Michelle Goldberg, Has Child Protective Services Gone Too
Far?, NATION (Sept. 30, 2015), https://www.thenation.com/
article/archive/has-child-protective-services-gone-too-far/
[https://perma.cc/ADW4-P95Z].
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abuse to CPS.361 Some legal activists and media assert that
healthcare providers’ notifications to CPS are punitive, will deter
women from seeking prenatal care, and cause unnecessary
harm.362 Despite such criticism, the goal of CPS is neither punitive
nor designed to disconnect family structures.363 Rather, CPS
serves as an intermediary for state intervention that provides
investigation that assesses the safety of the home environment.364
CPS also provides referrals for services such as substance abuse
treatment and parenting classes, a supervised case plan, and—
only where necessary—removes the child from the home.365 In
fact, multiple state laws explicitly clarify that the goal of CPS
intervention is to preserve the family structure or enable family
reunification.366
States that define prenatal substance abuse as child abuse
vary in a number of ways.367 There are differences as to the
amount of evidence required, whether the statute indicates
testing for the mother and/or infant upon birth when the provider
suspects maternal substance abuse, what level of evidence is
sufficient to initiate a report to CPS, and whether reporting to
CPS is required or discretionary.368 For example, California states
that a positive toxicology screen of the infant at birth alone is
insufficient to report suspected child abuse absent additional
factors, such as history of maternal substance abuse or other
evidence of suspected child abuse or neglect.369 Other states
specify that maternal substance abuse of controlled substances or
361. CHILD WELFARE INFORMATION GATEWAY, PARENTAL SUBSTANCE
USE AS CHILD ABUSE (2016) [hereinafter PARENTAL SUBSTANCE USE
AS CHILD ABUSE].
362. Paltrow, supra note 181, at 481; see also Martin, supra note 186.
363. PARENTAL SUBSTANCE USE AS CHILD ABUSE, supra note 361.
364. What is Child Protective Services?, STOP IT NOW, https://
www.stopitnow.org/ohc-content/what-is-child-protective-services
[https://perma.cc/KAU9-Z5D7] (last visited Jan. 30, 2022).
365. Id.; Logli, supra note 320, at 564-65.
366. CHILD WELFARE INFORMATION GATEWAY, REASONABLE EFFORTS
TO PRESERVE OR REUNIFY FAMILIES AND ACHIEVE PERMANENCY
FOR CHILDREN (2019) [hereinafter PRESERVE OR REUNIFY FAMILIES].
367. See id.
368. Id.
369. CAL. PENAL CODE § 11165.13 (West 2001).
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alcohol constitutes child abuse when it becomes “habitual or
excessive”370 or reflects “chronic or severe use,”371 suggesting that
these states aim to separate minor or isolated incidents from
pregnant women who engage in a pattern of ongoing substance
abuse. To compare, other states specify that infant withdrawal
symptoms or the presence of any controlled substance and/or
alcohol at birth by toxicology screen constitutes a sufficient basis
to begin an investigation.372
Importantly, several states clarify that the basis for
intervention does not apply to maternal use of legitimately
prescribed substances, which would apply to mothers enrolled in
MAT.373 However, based on rates of both relapse and ongoing
substance abuse for pregnant and parenting women enrolled in
MAT, their status of being in treatment should not preclude
either the mother or infant from undergoing toxicology screening.
Failing to screen mothers and infants based on treatment status
could exclude mothers who are struggling with treatment and
infants who are at-risk from ongoing substance abuse. Finally,
multiple states specifically limit the scope of culpability to civil
child welfare interventions and further specify that positive
toxicology results of the infant at birth shall not be used for
criminal prosecution purposes.374
State laws also specify the point at which parental substance
abuse constitutes child abuse or neglect within the home
environment.375 These laws also implicate instances when the
mother takes the infant home from the hospital and also pertains
370. MINN. STAT. § 260E.31 (2020).
371. LA. CHILD. CODE ANN. art 603(22) (2017).
372. Ch. 325 ILL. COMP. STAT. ANN. 5/3 (LexisNexis 2019); Ch. 325 ILL.
COMP. STAT. ANN. 5/7.3b (LexisNexis 2019); Ch. 705 ILL. COMP.
STAT. ANN. 5 (LexisNexis 2019); IND. CODE ANN. § 31-34-1-10
(West 2019); IND. CODE ANN. § 31-34-1-11 (West 2019); IOWA
CODE § 232.2(6) (2022).
373. COLO. REV. STAT. § 19-1-103(1)(a) (2016); FLA. STAT. ANN.
§ 39.01(34)(a)(2) (West 2021); FLA. STAT. ANN. § 39.01(34)(g)
(West 2021).
374. IOWA CODE § 232.77(2) (2022); LA. CHILD. CODE ANN. art. 610(G)
(2009); KY. REV. STAT. ANN. § 214.160 (West 2011); MO. REV.
STAT. § 191.737 (2019).
375. See Hollie Hendrikson & Kate Blackman, State Policies Addressing
Child Abuse and Neglect, NAT’L CONF. ST. LEGISLATURES (2015).
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to other children present in the home. According to the
Administration for Children and Families, these actions include
exposing children to illegal drug activity, such as: exposing a child
or allowing a child to be present where controlled substances are
stored, giving drugs or alcohol to a child, using a controlled
substance that impairs the parent’s ability to care for the child,
or exposing the child to the sale or distribution of drugs.376 In
some states, exposing or providing drugs to a child constitutes a
criminal felony defined as “chemical endangerment” or
“endangering the welfare of the child,” where state law specifies
more serious felony violations depending on whether the child
suffers harm or dies as a result.377
C.

Civil Commitment Laws Pertaining to Substance Abuse

Some states have adopted an approach to address habitual,
chronic, or excessive substance abuse by enacting specific laws
that permit civil commitment in certain circumstances.378 Many
states have civil commitment laws designed to facilitate a process
for involuntary commitment for the purpose of substance abuse
treatment, applicable to the general class of all persons with
SUD.379 These laws apply in narrow circumstances in which the
person with SUD exhibits chronic, habitual, or excessive use of
drugs and or alcohol and is incapacitated by substance abuse to
an extent they can no longer provide for their basic needs, or
there is reason to believe they will likely harm another by their
conduct if they are not detained in treatment.380 A very small
minority of states have additional laws addressing pregnant
376. PARENTAL SUBSTANCE USE AS CHILD ABUSE, supra note 361.
377. ALA. CODE § 26-15-3.2 (2012); DEL. CODE ANN. tit. 11 § 1102
(West 2022); N.D. CENT. CODE ANN. § 19-03.1-22.2 (West 2021).
378. Megan Hull, Involuntary Commitment Laws, RECOVERY VILL.
(Nov. 9, 2021), https://www.therecoveryvillage.com/mentalhealth/related/involuntary-commitment-laws/ [https://perma.cc/
D7H2-37ZS].
379. See Involuntary Commitment for Individuals with Substance Use
Disorder or Alcoholism, NAT’L ALLIANCE MODEL ST. DRUG L., Aug.
2016, at 1, 3; Commitment and Guardianship Laws for Persons
with a Substance Use Disorder, NAT’L CTR. ST. CTS. (Oct. 2018),
https://www.ncsc.org/~/media/4EC4A03001EB4E5BB5F649FE2
D4F7802.ashx [https://perma.cc/R7LB-PU4U].
380. Commitment and Guardianship Laws for Persons with a Substance
Use Disorder, supra note 379.

377

Health Matrix·Volume 32·2022
Treating for Two

women as a class who engage in habitual, chronic, excessive, or
uncontrollable substance abuse, and provide a similar procedure
for civil commitment to facilitate treatment.381 As with other laws
for civil commitment, state procedures must comport with due
process: providing notice, an opportunity to object, a chance to
assess evidence supporting the reason for commitment, and using
the least restrictive method of treatment.382
Some states, such as Oklahoma, specifically indicate that it
would like to address the problem of prenatal substance abuse by
offering treatment.383 The legislature also recognizes that not all
pregnant women with habitual SUD will seek treatment and, in
some cases, the state should have the authority to intervene.384
Oklahoma law notes the state’s interest in preventing harm to
children from excessive substance abuse during pregnancy and
mitigating the cost of providing medical care.385
Some stakeholders argue that these laws target pregnant
women, amount to unlawful and arbitrary physical restraint,
constitute forced medical treatment, and violate fundamental
human rights.386 Indeed, any laws that curtail individual liberties,
particularly in the context of civil commitment for treatment,
must be fastidiously applied to guard against overreach, misuse,
or abuse. But these laws do not aim to restrict pregnant women’s
rights. Rather, they are meant to address a behavior of severe
habitual substance abuse, and should be viewed as an extension
of similar laws that apply to all adults exhibiting such behavior.
381. Cynthia Soohoo & Risa Kaufman, The Detention and Forced

Medical Treatment of Pregnant Women: A Human Rights
Perspective, AM. CONST. SOC. L. & POL’Y (Mar. 2018), https://
www.acslaw.org/issue_brief/briefs-landing/the-detention-andforced-medical-treatment-of-pregnant-women-a-human-rightsperspective/ [https://perma.cc/LB4G-GD7]; see also OKLA. STAT.
ANN. tit. 3 § 1-546. (West 2021); MINN. STAT. § 253B.02 (2021);
S.D. CODIFIED LAWS § 34-20A-63, 34-20A-70 (2022); WIS. STAT.
ANN. § 48.133 (West 1997).
382. City of Newark v. JS, 652 A.2d 265, 274-75 (N.J. Super. Ct. Nov.
8, 1993).
383. OKLA. INTERAGENCY CHILD ABUSE PREVENTION TASK FORCE,
OKLAHOMA STATE PLAN FOR THE PREVENTION OF CHILD ABUSE AND
NEGLECT 11, 47-48 (2014).
384. OKLA. STAT. ANN. tit. 3 § 1-546. (West 2021).
385. Id.
386. Soohoo & Kaufman, supra note 381.
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Moreover, the laws do not serve a punitive function by detaining
and jailing women for no reason, as commonly described in media
reports.387
In one controversial case, Loertscher v. Anderson, Tamara
Loertscher sought medical treatment for hypothyroidism and
prenatal care.388 Loertscher tested positive for methamphetamine,
amphetamine, and tetrahydrocannabinol, and asserted that she
was “self-medicating” with illicit substances and alcohol.389
Loertscher reported that, when she learned that she was pregnant,
she “cut back” from daily drug abuse to less frequent drug and
alcohol abuse at a rate of two to three times per week.390 Her
medical record at the time indicated she was aware she was
pregnant, was diagnosed with polysubstance abuse, and abused
alcohol to the point of losing consciousness during her
pregnancy.391
Under the state’s civil commitment law, the court considered
not only evidence of Loertscher’s substance abuse, but also her
obstetrician’s testimony that Loertscher had refused prior offers
for treatment while simultaneously continuing polysubstance
abuse.392 The court initially ordered Loertscher to report to a
substance abuse treatment facility for assessment and possible
treatment.393 Loertscher ignored the court order, failed to comply,
and as a result, the court found Loertscher in contempt, after
which she was briefly detained in jail.394 In response, media
reports decried the Wisconsin law as a draconian tool for
imprisoning women because they are pregnant.395 To clarify, the
387. See, e.g., Sara Finger, Women Are Treated Shamefully Under
Wisconsin’s “Cocaine Mom” Law, HUFF POST (Apr. 18, 2017),
https://www.huffpost.com/entry/wisconsins-dirty-secret-aboutthe-treatment-of-pregnant_b_58efdd88e4b0156697224d94
[https://perma.cc/7J6W-UBEG].
388. Loertscher v. Anderson, 893 F.3d 386, 390 (7th Cir. 2017).
389. Id.
390. Id.
391. Id.; Loertscher v. Anderson, 259 F. Supp. 3d 902, 909-10 (W.D.
Wis. 2017).
392. Loertscher, 893 F.3d at 390-91.
393. Id. at 391.
394. Id.
395. Finger, supra note 387.
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court did not order Loertscher to a brief jail sentence for no
reason, nor based on her substance abuse; rather, anyone who
violates a court order may be placed in contempt.396 Courts must
have a measure of accountability to ensure compliance with orders
for any person under its jurisdiction.
Under the Wisconsin state law at the time, if the CPS
investigation and medical reports suggested that a pregnant
mother engaged in habitual and excessive substance abuse, the
care team offered treatment, and the mother refused, then CPS
could petition the court for an order of civil commitment to
facilitate treatment.397 Loertscher insisted that she did not need
substance abuse treatment despite continued substance abuse.398
Incidentally, Loertscher’s treatment plan only required her to
attend regularly scheduled prenatal appointments and submitting
urine toxicology screens.399
Loertscher challenged the constitutionality of the Wisconsin
law, asserting that it amounted to forced medical treatment,
arbitrary detention, and a violation of liberty, privacy, and bodily
integrity.400 Though the 7th Circuit Court of Appeals found the
suit moot on technical grounds,401 the case raises the question of
whether civil commitment may be an appropriate mechanism to
facilitate treatment in narrow circumstances for pregnant
mothers with severe and habitual SUD. Loertscher’s case
highlighted the importance of cautiously adhering to due process
safeguards. This includes reviewing evidence from multiple
sources including the pregnant women herself, avoiding any
orders that require the patient to use medication based on serious
risks from opioid agonists, and opting for the least restrictive
alternative. If the pregnant patient insists that she does not want
or need treatment, the least restrictive alternative could reflect
this by merely ordering toxicology screens to monitor whether the
patient’s stated lack of need for treatment is accurate.

396. Loertscher, 893 F.3d at 391.
397. Loertscher v. Anderson, 259 F. Supp. 3d 902, 907 (W.D. Wis.
2017).
398. Loertscher, 893 F.3d at 390.
399. Id. at 391.
400. See Soohoo & Kauffman, supra note 381.
401. Loertscher, 893 F.3d at 396.
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1.

Defining Maternal Substance Abuse in Criminal Law
Prenatal Substance Abuse is NOT a Crime in Most States

In the vast majority of states, maternal substance abuse is
not classified as a crime.402 At the time of this writing, only
Alabama and South Carolina define substance abuse during
pregnancy as a distinct crime.403 In states where maternal
substance abuse is not a crime, prosecutors have been largely
unsuccessful when bringing criminal charges related to prenatal
substance abuse. They have been brought under the umbrella of
criminal child abuse, reckless endangerment or injury to a child,
or homicide when maternal drug abuse results in the transfer of
drugs to a born alive infant and causes death.404 Contrary to the
position that abusing drugs during pregnancy merely constitutes
a neutral social choice, many defendants in such cases engaged in
an ongoing pattern of habitual substance abuse that caused severe
damage. This harm includes brain death of the infant;405
morbidities such as respiratory arrest, extreme prematurity and
low birth weight; or infant death.406 Prosecutors have
(unsuccessfully) attempted to bring charges against mothers who
engaged in habitual prenatal substance abuse where an infant was
born alive, but subsequently died days or weeks after birth as a
result of acute intoxication.407 Even in cases that involved death
of an infant – not a fetus – the majority of courts have dismissed
such charges or overturned convictions.408 Though this class of
402. GUTTMACHER, supra note 325.
403. Id.; see Ex Parte Ankrom, 152 So. 3d 397, 401 (Ala. 2013) (holding
the state’s chemical endangerment statute did apply to prenatal
substance affecting unborn children); Whitner v. State, 492 S.E. 2d
777, 786 (S.C. 1997) (holding the child abuse and endangerment
statute did apply to prenatal substance abuse affecting unborn
children).
404. See

Cara Angelotta & Paul Appelbaum, Criminal Charges for
Child Harm from Substance Use During Pregnancy, 45 J. AM.
ACAD. PSYCHIATRY & L. 193, 193 (2017).

405. State v. Louk, 786 S.E.2d 219, 222 (W. Va. 2016).
406. Ross et al., supra note 196, at 64, 68-69.
407. Kilmon v. State, 905 A.2d 306, 308, 315 (Md. Ct. App. 2006); see
also Louk, 786 S.E.2d at 222; Johnson v. State, 602 So.2d 1288,
1291 (Fla. 1992); State v. Aiwohi, 123 P.3d 1210, 1210 (Haw. 2005).
408. Angelotta & Appelbaum, supra note 404; Johnson, 602 So.2d at
1296 (dismissing drug delivery charges, holding the legislature did
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cases involves defendants with multiple types of substance abuse,
the central questions of criminal responsibility similarly apply.
To underscore, these cases exemplify instances where harm to
the infant did not result from one isolated incident of substance
abuse, but rather reflected a pattern of long-term habitual
substance abuse. In Johnson v. State, Jennifer Johnson admitted
to smoking marijuana and crack cocaine three to four times every
other day throughout the duration of her pregnancy, including
the night prior to delivery.409 In that case, the prosecutor adopted
the theory that prenatal substance abuse constituted a crime
because it delivered drugs through the umbilical cord following
delivery to her infant, an existing child at the time of
commission.410 In State v. Aiwohi, Tayshea Aiwohi admitted that
she smoked crystal meth every day leading up to delivery and
continued daily drug abuse while breastfeeding her infant, who
subsequently died of acute drug intoxication after she took him
home from the hospital.411 Notably, Aiwohi was enrolled in
substance abuse treatment during this time, yet still continued
habitual substance abuse.412
In Johnson’s case, she admitted to ongoing polysubstance
abuse during both of her two pregnancies, and both of her children
were born with illicit substances in their system.413 CPS had been
not intend to authorize prosecution of mothers for umbilical cord
delivery); see also Kilmon, 905 A.2d at 307 (holding reckless
endangerment statute does not apply to conduct of pregnant
women); Louk, 786 S.E.2d at 219 (holding that child endangerment
statute does not encompass prenatal acts that result in physical
harm to the subsequently born child); Aiwohi, 123 P.3d at 1210
(holding the homicide statute did not apply to prenatal conduct
that subsequently caused the infant’s death).
409. Johnson, 602 So. 2d at 1291; see also Ex Parte Ankrom, 152 So. 3d
397, 397 (Ala. 2013) (where Hope Ankrom tested positive for
cocaine and marijuana multiple times throughout her pregnancy).
410. Johnson, 602 So. 2d at 1290.
411. Aiwohi, 123 P.3d at 1211.
412. Id.
413. Johnson, 602 So. 2d at 1291 (Johnson admitted to substance abuse
during both of her two pregnancies); see also Kounang, supra note
1 (discussing Samantha Jones, where Jones admitted to substance
abuse during her pregnancy that resulted in losing consciousness
while in a motor vehicle and her other child was also in that
vehicle).
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involved, prior to the death of her infant, to investigate
allegations of substance abuse and reports of child abuse against
another child in the home; yet her children remained in her care.414
Aiwohi’s and Johnson’s cases exemplify the potential
insufficiency of relying on CPS. The unfortunate consequence of
ongoing substance abuse, even while in treatment, and delayed
intervention is that the child may become injured or die.
Prosecution for prenatal transfer of illicit substances has been
unsuccessful in most jurisdictions because courts have held that
the victim of the crime must be in the class of offenders at the
time of commission.415 Accordingly, even if prenatal substance
abuse results in the transfer of illicit substances to a born-alive
infant or causes that infant’s death, this does not constitute a
crime in these jurisdictions.416 State v. Aiwohi references a long
list of precedent across multiple jurisdictions which held that even
if the mother’s conduct demonstrated “reckless indifference” and
“created a substantial risk of death or great bodily harm to the
subsequently born child,” such conduct would only constitute a
crime when it was directed against another person or human
being at the time of commission.417 These courts also clarify that
the fetus does not constitute a person or another human being.418
For some courts, this distinction exists based on separation
of powers and policy considerations.419 Courts must discern
legislative intent to determine what acts constitute a crime, and
some courts have adopted a narrow view: if the legislature does
not specify that prenatal substance abuse constitutes a separate
414. Id.
415. Aiwohi, 123 P.3d at 1212; State v. Louk, 786 S.E.2d 219, 223-24
(W. Va. 2016); Kilmon v. State, 905 A.2d 306, 312 (Md. Ct. App.
2006).
416. Kilmon, 905 A.2d at 312.
417. Aiwohi, 123 P.3d at 1216.
418. Id. at 1223. But see Whitner v. State, 492 S.E.2d 777, 780-81 (S.C.
1997); Ex Parte Ankrom, 152 So. 3d 397, 412 (Ala. 2013); ALA.
CODE § 13A-6-1 (2006) (defining “person,” for the purpose of
criminal homicide or assaults, to include an unborn child in utero
at any stage of development, regardless of viability); S.C. CODE
ANN. § 16-3-1083 (2006) (defining “unborn child” as a child in
utero, and “child in utero” or “child who is in utero” as a member
of the species Homo sapiens, at any state of development, who is
carried in the womb).
419. Whitner, 492 S.E. 2d at 780.
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crime or that acts against a fetus constitute a crime, then the
court will not permit prosecution.420 While integrating policy
considerations, some courts have questioned whether permitting
prosecution constitutes the most effective solution.421 These courts
cite position statements from the American Medical Association
and APHA that disfavor prosecution for prenatal substance abuse
as reasons for foreclosing such acts from being considered
crimes.422 Moreover, state courts in Florida and West Virginia
have expressed concerns that permitting prosecution of pregnant
women would create a slippery slope and “proscribed conduct
would be impermissibly broad and ill-defined.”423 The court in
Kilmon v. State opined that permitting prosecution for prenatal
substance abuse within the scope of reckless endangerment would
open the door to an untenably broad list of other conduct.424
Courts could punish women for maintaining an improper diet, not
wearing a seatbelt, exercising too much or too little, or bearing a
child with a genetic disability.425
Despite Kilmon’s fear of a slippery slope, ongoing
polysubstance abuse is not a neutral, ordinary activity or exercise
in value judgment as compared to choices about food and
exercise, because possession of illicit substances already
constitutes a crime.426 The dissent in State v. Louk convincingly
addressed this issue, stating, “It is common knowledge that use of
illegal substance by pregnant mothers subject their unborn
children to high risk of injury. The petitioner readily admitted
she knew injecting methamphetamine into her vein would put
[the fetus] at risk. She simply chose to disregard Olivia’s welfare.
She should be held accountable for her actions.”427 Indeed, even
activities such as race car driving, sky diving, or disarming
explosive devices while pregnant may be risky, but still do not
meet the clear demarcation of an activity that constitutes both
420. Louk, 786 S.E.2d at 228; Johnson v. State, 602 So.2d 1288, 1291
(Fla. 1992); Kilmon, 905 A.2d at 312; Aiwohi, 123 P.3d at 1223.
421. Johnson, 602 So. 2d at 1296.
422. Id.
423. Louk, 786 S.E.2d at 225.
424. Kilmon, 905 A.2d at 311.
425. Id.
426. Id. at 314.
427. Louk, 786 S.E. 2d at 237 (Loughry, J., dissenting).
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existing illegal conduct and certain harm to the fetus—rendering
the fear of a slippery slope unconvincing.
Finally, though most jurisdictions do not permit prosecution
for maternal substance abuse even when it leads to injury and
death of the infant, the majority of jurisdictions (thirty eight
states) do permit prosecution for acts against the fetus committed
by a third party through specific fetal homicide laws.428
Jurisdictions that contain fetal homicide laws vary as to whether
they recognize any rights of the fetus or whether the law classifies
the harm as depriving the mother of her pregnancy without her
consent (as to distinguish fetal homicide from legal abortion.).429
The comparison of maternal conduct versus third-party conduct
creates a dilemma, because some fetal homicide laws apply even
if there is no born-alive infant, where the third party’s conduct
causes the death of the fetus.430 Moreover, twenty-nine states
recognize fetal homicide as a crime even in early stages of
pregnancy.431 This raises the difficult question of why states
recognize the criminal nature of conduct perpetrated against
fetuses that cause injury or death by third parties, but do not
criminalize egregious illegal acts by the mother. As the court in
State v. Aiowhi observed, “[T]he two propositions cannot logically
co-exist,” leading the court to only recognize claims for offenses
perpetrated against an existing child, — that is, crimes against a
child that occur after the child has been born.432
2.

Consequences of Exempting Prenatal Acts from Prosecution

Courts’ unwillingness to permit prosecution for conduct that
impacts an existing infant constitutes a troublesome gap in the
law and poses the question of why the courts choose not to hold

428. State Laws on Fetal Homicide and Penalty-Enhancement for
Crimes Against Pregnant Women, NAT’L CONF. ST. LEGISLATURES
(May 1, 2018) [hereinafter State Laws on Fetal Homicide],
http://www.ncsl.org/research/health/fetal-homicide-state-laws.
aspx [https://perma.cc/YQK8-8SGW]; see also Louk, 786 S.E.2d
at 226; Kilmon, 905 A.2d at 310; State v. Aiwohi, 123 P.3d 1210,
1218 (Haw. 2005).
429. State Laws on Fetal Homicide, supra note 428.
430. Aiwohi, 123 P.3d at 1218.
431. State Laws on Fetal Homicide, supra note 428.
432. Aiwohi, 123 P.3d at 1221.
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the mother accountable for an infant’s preventable death.433 First,
this stance appears to be fueled by distorting privacy and
reproductive liberty arguments ordinarily used during the
prenatal period and advocating for those arguments’ application
to already-born infants. Second, this narrative relies on the
perspective that persons acting as a result of their addiction have
lost control over their actions and should not be criminally
punished. Though addiction is not a crime, prosecution targets
specific crimes that directly impact the welfare of society, which
may be motivated or influenced by the individual’s drug abuse.434
The key issue becomes disentangling private substance abuse
from substance abuse connected to actions that affect other
persons, the public safety, or that are linked to other crimes.435
Johnson v. State viewed the delivery of controlled substances
as an incidental outcome of the mother’s substance abuse, but not
as a distinct crime.436 Adopting materials from the AMA Board
of Trustees Report, the court in Johnson reasoned that courts
should not punish people for substance abuse because they have
impaired capacity for decision-making and do not intend to harm
the fetus.437
Courts addressing the issue of addiction and free will have
held that even if addiction constrains choice, it does not negate
free will: persons still make choices, and may still be held
accountable by the judicial system when they commit a crime.438
They may also face liability for violating a court order to comply
with substance abuse treatment even if the action was linked with
the defendant’s underlying substance abuse.439 Indeed, one of the
433. See Logli, supra note 320, at 566 (stating that ignoring a newborn’s
death is “simply unconscionable.”).
434. Drabiak, supra note 14.
435. See id. at 19.
436. Johnson v. State, 602 So.2d 1288, 1292 (Fla. 1992).
437. Id. at 1295 n.5.
438. Powell v. Texas, 392 U.S. 514, 526 (1968).
439. See id. at 519 (Powell, an alcoholic who had been arrested 100 times
for public intoxication made a conscious decision to have only one
drink the morning before his court appearance because he did not
want to “pass out or be picked up” and miss the court appearance).
See also Commonwealth v. Eldred, 101 N.E.3d 911, 924 (2018)
(holding the court may exercise its authority to prohibit illicit
substance abuse, particularly when substance abuse is directly
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seminal cases distinguishing addiction from crimes that affect
public safety and welfare was Robinson v. California.440 In
Robinson, the Supreme Court held: “There can be no question of
the authority of the State . . . to regulate the . . . use
of . . . drugs [through, inter alia] a program of compulsory
treatment for those addicted to narcotics[,]. . .[even requiring]
involuntary confinement [and] penal sanctions for failure to
comply with established compulsory treatment procedures.”441
The Court distinguished a defendant’s status as a person with
addiction from the action of abusing substances, recognizing that
the latter poses risk to society and may constitute a criminal
violation.442
Problematically, the push to use substance abuse as an
exculpatory factor has extended into excusing maternal conduct
toward infants during the postpartum period, as illustrated in the
Samantha Jones case.443 All states – even states that adopt of
policy of non-intervention for prenatal substance abuse – must
demarcate that the delivery of controlled substances to an infant
after birth undoubtedly constitutes a criminal action. To be sure,
no one has the right to abuse children by delivering drugs into
their system, not even their parents.
3.

Only a Very Small Minority of States Consider Prenatal
Substance Abuse a Crime

Grappling with the problem of ongoing substance abuse
during pregnancy, only two states, Alabama and South Carolina,
recognize substance abuse during pregnancy as a crime.444
Notably, from 2014-2016, Tennessee briefly had a law that
classified prenatal substance abuse within its criminal assault
framework.445 It classified assault as the illegal use of narcotics
while pregnant that resulted in infant dependence or death of the
related to associated crimes, such as Eldred’s theft as a method to
purchase more drugs).
440. Robinson v. California, 370 U.S. 660, 664 (1962).
441. Id.
442. Id. at 666.
443. See Menno supra note 6.
444. Whitner v. State, 492 S.E.2d 777, 786 (S.C. 1997); Ex Parte
Ankrom, 152 So. 3d 397, 429 (Ala. 2013).
445. TENN. CODE ANN. § 39-13-107 (2015).
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infant once born.446 The Tennessee law further recognized
enrollment and sustained engagement in treatment as an
affirmative defense.447 That law contained a sunset provision
which caused it to expire in 2016.448 Legislators have
unsuccessfully tried to re-introduce a similar bill in Tennessee.449
The Tennessee law was highly controversial: some critics referred
to the law as criminalizing women and pregnancy,450 while
Tennessee State Representative, Terri Weaver, insisted the law
was intended as a measure of accountability that would motivate
recalcitrant women with severe addiction to enter treatment.451
Two notable courts in Whitner v. State452 and Ex Parte
Ankrom453 deviate from most jurisdictions in their treatment of
prenatal substance abuse.
a.

Whitner v. State

In Whitner v. State, Cornelia Whitner was charged with
criminal child neglect pursuant to South Carolina’s child abuse
and endangerment statute when she admitted to smoking crack
cocaine during her pregnancy.454 Her actions caused her third
child, Tevin, to be born with cocaine metabolites in his system.455
The case did not reflect an isolated incident, but rather a pattern
of conduct by a mother who routinely placed her children at risk.
From the time she was a teenager, Whitner struggled with
addiction, abusing marijuana, alcohol, cocaine, and crack

446. Id. §§ 39-13-107, 39-13-214.
447. Id. § 39-13-107.
448. Id.
449. AMNESTY INT’L, supra note 314, at 7-8.
450. Id.
451. Mallory Yu, In Tennessee, Giving Birth to a Drug Dependent Baby
Can Be a Crime, HOUS. PUB. MEDIA (Feb. 10, 2017), https://
www.houstonpublicmedia.org/npr/2017/02/10/455924258/intennessee-giving-birth-to-a-drug-dependent-baby-can-be-a-crime/
[https://perma.cc/4GVE-FAT4].
452. Whitner v. State, 492 S.E.2d 777, 782 (S.C. 1997).
453. Ex Parte Ankrom, 152 So. 3d 397, 404 (Ala. 2013).
454. Whitner, 492 S.E.2d at 778-79.
455. Id. at 779; see also Levinson, supra note 332.

388

Health Matrix·Volume 32·2022
Treating for Two

cocaine.456 To fund her addiction, Whitner relied on theft and
prostitution, allegedly leaving her children unattended without
food for days and disappearing after leaving them with
relatives.457 While pregnant with Tevin, Whitner was charged
with child neglect of her existing two children; the presiding judge
sentenced her to probation on the condition she avoid drugs and
alcohol and avoid further legal trouble.458 Two months later,
Whitner appeared before the same presiding judge, charged with
criminal child abuse and endangerment for delivering cocaine
metabolites into Tevin’s system.459
Whitner addressed the question of whether the legislature
intended for the state’s child endangerment statute to apply to
“unborn children.” The court reasoned that it is the policy of the
state to protect children from harm, accepting through judicial
notice that recurrent prenatal substance abuse can cause serious
harm to children.460 Examining fetal homicide laws as a
comparison, Whitner opined it would be “unsound, illogical, and
unjust” to recognize harm to the fetus from a third party, but to
insulate the mother from culpability for acts that would also harm
or injure the fetus.461 The Whitner court held that the fetus has
an independent right to protection from the state.462 Remarkably,
Whitner cited oft-forgotten precedent from Roe v. Wade and
Planned Parenthood v. Casey that recognized – and balanced –
competing interests of pregnant women and fetuses.463 The Roe
court held that the state’s protection of the life and health of a
viable fetus is not merely legitimate, but the state’s interest
becomes compelling at the point of viability.464 The court in Casey
went further, holding that the state professes a “substantial

456. Levinson, supra note 332.
457. Id.
458. Id.
459. Id.
460. Whitner, 492 S.E.2d at 782.
461. Id. at 780.
462. Id. at 783.
463. Id. at 785-86. See also Roe v. Wade, 410 U.S. 113, 193 (1973);
Planned Parenthood v. Casey, 505 U.S. 833, 867 (1992).
464. Whitner, 492 S.E.2d at 785-86; Roe, 410 U.S. at 193.
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interest” in protecting potential life of the fetus not only after
viability but throughout the entire pregnancy.465
Whitner argued that applying the statute constituted an
invasion of her privacy.466 The court in Whitner dismissed her
argument that applying the child endangerment statute to
conduct during pregnancy infringes upon women’s right to
privacy, and said that it “strains belief” to argue that abusing
crack cocaine during pregnancy should be encompassed within a
right to privacy because such conduct is already illegal.467
According to Whitner, including “unborn children” within the
scope of the child endangerment law neither criminalizes
pregnancy nor applies to seeking an abortion, but rather
recognizes that certain actions during pregnancy already
constitute a crime.468
b.

Ex Parte Ankrom

Similar to Whitner, the court in Ex Parte Ankrom addressed
whether the state’s criminal chemical child endangerment statute
included unborn children.469 Ex Parte Ankrom involved two
separate defendants, Hope Ankrom and Amanda Kimbrough.470
On several occasions throughout her pregnancy, Ankrom
tested positive for cocaine and marijuana, and prior to the birth
of B.W. she again tested positive for cocaine.471 When Ankrom’s
son B.W. was born and tested positive for cocaine metabolites,
Ankrom was charged and pled guilty to violating the state’s child
endangerment statute that criminalized causing a child to be
exposed to, to ingest or inhale, or to have contact with a
controlled substance.472
During her pregnancy with her third child Timmy, Amanda
Kimbrough’s physician and Timmy’s biological father both
465. Casey, 505 U.S. at 867.
466. Whitner, 492 S.E.2d at 777.
467. Id. at 768. To be sure, crimes connected to controlled substances
pertain to possession, distribution, or public intoxication, rather
than ingestion.
468. Id.
469. Ex Parte Ankrom, 152 So. 3d 397, 397-98 (Ala. 2013).
470. Id. at 397.
471. Id. at 402.
472. Id. at 430.
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confronted her about her methamphetamine abuse, which she
denied.473 At 25 weeks into the pregnancy, Kimbrough went into
preterm labor, delivering Timmy via Caesarian section.474 Born
alive but not breathing, Timmy was intubated and placed on a
ventilator. Timmy died nineteen minutes after birth.475 The
medical examiner who performed an autopsy on Timmy
determined that the cause of death was acute methamphetamine
toxicity transferred by Kimbrough.476 In a subsequent interview
with CPS, Kimbrough admitted to methamphetamine abuse
during pregnancy, prior to Timmy’s preterm birth.477
The court in Ex Parte Ankrom held that Alabama state
public policy protects the life of unborn children, particularly
when the unborn life is capable of living outside the womb, in
recognition that every child is entitled to live in safety, in a
reasonably healthy environment, and survive into adulthood.478
Citing Whitner, the Ex Parte Ankrom court also held that fetal
homicide laws provided comparable precedent to permit
prosecution for acts that injure or cause the death of a viable
fetus.479 Indeed, the Ex Parte Ankrom court reasoned that “it
would be absurd to recognize the fetus as a person for homicide
and wrongful death statutes, but not for statutes proscribing child
abuse.”480 Stating that the court was unconvinced by the majority
of jurisdictions that do not recognize the application of criminal
child endangerment statutes as applied to fetuses, the court
reasoned that it could not abandon common sense.481 To support
its reasoning, the court looked to dictionary definitions of “child;”
Merriam-Webster’s Dictionary defined child to include an
“unborn or recently born person” and Black’s Law Dictionary
included “a baby or fetus” within the definition of “child.”482
473. Id. at 403.
474. Id.
475. Id.
476. Id.
477. Id. at 404.
478. Id. at 404, 416.
479. Id. at 423.
480. Id. at 406.
481. Id. at 409.
482. Id. at 411.
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Accordingly, in Alabama, delivery of a controlled substance to
the fetus constitutes a crime at the time of infliction, and includes
all “unborn children” without distinction to viability.483
Whitner and Ex Parte Ankrom stand in the minority of most
decisions; most jurisdictions dismiss charges and overturn
convictions of pregnant mothers’ conduct of habitual substance
abuse during pregnancy that cause harm to, or the death of, their
born infant.484 Many courts appear to be locked into inaction: the
concurrence in State v. Louk acknowledged that “however
addiction may explain irresponsible behavior, it does not excuse
it,” but lamented that the state’s law was “inadequate to address
this tragedy.”485 Writing for the dissent in State v. Louk, Justice
Loughry convincingly argued that the court should not have
looked at the status of the victim when the crime occurred.486
Rather, infants born alive who died from prenatal drug toxicity
or related complication following their birth died by reason of a
chain of circumstances: the pregnant mother’s drug abuse was the
causal factor of a child’s injury or death, an action or series of
actions for which the law should hold her criminally responsible.487

V.

POLICY SOLUTIONS TO ADDRESS PRENATAL SUBSTANCE
ABUSE

Integrating varied state law responses, this section will discuss
the concept of a prenatal duty and offer policy strategies to
initiate both healthcare and legal intervention during the prenatal
period to most effectively address prenatal substance abuse.
A.

Defining Prenatal Duty

Some legal scholars and courts adopt the position that the
state not only has a duty to protect children, but also holds a duty
to protect the health of the unborn.488 This places a corresponding
483. Id. at 416.
484. See generally Krista Stone-Manista, Protecting Pregnant Women: A

Guide to Successfully Challenging Criminal Child Abuse Prosecutions
of Pregnant Drug Addicts, 99 J. CRIM. L. & CRIMINOLOGY 823 (2009).
485. State v. Louk, 786 S.E.2d 219, 229 (W. Va. 2016).
486. Id. at 234-35.
487. Id. at 237.
488. Logli, supra note 320.

392

Health Matrix·Volume 32·2022
Treating for Two

duty on pregnant mothers to maintain a minimum standard of
care.489 Legal scholars Andrew Weisberg and Frank Vandervort
note that substance abuse during pregnancy increases the risk of
inflicting serious and lasting harm on the future child, underscore
that each incident imposes an entirely avoidable, unnecessary,
and unacceptable risk, and remark that the resulting harm can
be severe or permanent.490 Attorney Patricia Congdon (adopting
arguments from Roe and Casey) asserts that there is a legally
binding obligation to refrain from endangering or neglecting the
fetus through substance abuse, particularly once the pregnant
mother has accepted the pregnancy.491
This applies not only to substance abuse, but also to conduct
that far deviates from a minimal standard of care such that it
causes demonstrable harm to the infant. In People v. Pointer, the
court addressed a mother whose diet was so excessively restrictive
she suffered from such severe malnutrition and starvation
throughout her pregnancy that caused her infant to be born with
“severe growth retardation and permanent neurological
damage.”492 This mother also had other children in her care who
were malnourished and suffered discrete physical harm as a result
of her care.493 The Pointer court held that protecting the health
of unborn children was a legitimate government objective and
that the government had a duty to intervene, particularly where
the mother had no intention of modifying the actions that had
already caused harm to several of her children.494 Legal scholar
Phillip Johnson reasons that if the mother has a legal and moral
duty to refrain from starving her children or administering
controlled substances and alcohol to them after birth, there is no

489. Id.; Philip Johnson, The ACLU Philosophy and the Right to Abuse
the Unborn, 9 CRIM. JUST. ETHICS 48, 50 (1990); Andrew J.
Weisberg & Frank E. Vandevort, A Liberal Dilemma: Respecting

Autonomy While Also Protecting Inchoate Children From Prenatal
Substance Abuse, 24 WM. & MARY BILL RTS. J. 659, 660 (2016).
490. Weisberg & Vandevort, supra note 489, at 670, 702.
491. Patricia R. Congdon, Note, Prenatal Prosecution: Taking a Stand
for the State and the Well-Being of its Soon-to-Be Citizens, 5
CHARLESTON L. REV. 621, 643 (2011).
492. People v. Pointer, 151 Cal. App. 3d 1128, 1133 (Ct. App. 1984).
493. Id. at 1132.
494. Id.
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reason to exempt her from the same duty of care during
pregnancy.495
Parents have the primary responsibility to ensure the health,
safety, and well-being of their children, and as such they should
not be permitted to engage in objectively harmful behavior
toward their offspring.496 Accordingly, the state has a duty to
intervene in cases where a mother with substance abuse cannot,
or will not, take steps to protect her future infant or children.497
B.

Stepped Strategies to Address Prenatal Substance Abuse

Legal scholars Jeremiah Ho and Alexander Rovzar suggest a
facilitative approach, whereby the state shares the interest in
promoting both maternal and fetal health during pregnancy with
the pregnant patient.498 Ho and Rovzar suggest early
identification of substance abuse via universal screening and
toxicology testing as a method to identify pregnant women in
need of assistance or treatment, and suggest offering stepped care
based on each patient’s own treatment needs.499 Importantly, Ho
and Rovzar note the insufficiency of relying on substance abuse
screening after the infant is born because this model does not
address or remediate preventable prenatal substance abuse and
harm to the infant that occurred during the pregnancy.500 Health
care providers could offer treatment during the pregnancy, but
they may have insufficient resources to effectively assist with
referrals and follow-up and, acting alone, they would have no
means to produce accountability.
To facilitate the referral of treatment services and oversight,
states could notify CPS during the pregnancy rather than
following the infant’s birth.501 Ideally, CPS would assist with

495. Johnson, supra note 489, at 49.
496. Congdon, supra note 491, at 643.
497. Weisberg & Vandervort, supra note 489, at 706.
498. Jeremiah Ho & Alexander Rovzar, Preventing Neonatal Abstinence

Syndrome Within the Opioid Epidemic: A Uniform Facilitative
Approach, 54 HARV. J. LEGIS. 301, 332 (2017).
499. Id. at 392.
500. Id. at 305.
501. Weisberg & Vandervort, supra note 489, at 687; Ho & Rovzar,
supra note 498, at 318.
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providing the pregnant patient with information on effective
treatment programs for pregnant and parenting mothers.
Health professionals and policymakers should clarify that
state intervention through CPS functions as a method to facilitate
treatment and does not constitute an unwarranted or punitive
intervention. Even in states that classify prenatal substance abuse
as civil child abuse, media reports and recent cases exemplify how
this strategy still permits multiple cases to slip through the
cracks.502 In such cases, a carefully applied civil commitment
model could serve the dual roles of facilitating treatment for the
pregnant mother and preventing harm to the future infant.503
As an alternative for cases in which pregnant and parenting
women refuse or leave treatment, states may consider the role of
prosecution as a last resort for extreme circumstances. Criminal
prosecutor Paul Logli asserts that prosecutors have a duty to
protect all children and are thus bound to investigate reports of
infants exposed or dependent on controlled substances or
alcohol.504 No prosecutor, according to Logli, can stand by while
a child is allowed go home with a parent who is actively engaging
in substance abuse because there is a high probability that the
child will re-enter the system as a victim of abuse or neglect.505
Logli and Johnson agree that prosecution should serve as a force
for accountability and assistance, by first offering treatment and
utilizing strategies such as deferred prosecution to foster
rehabilitation.506 If the pregnant woman who is engaging in
substance abuse successfully adheres to the drug treatment
program and refrains from substance abuse, then the court should
dismiss any criminal charges.507 If, however, the pregnant woman
refuses treatment or continues substance abuse, Logli and
Johnson suggest that the courts may then use punitive
measures.508 Criminal prosecution in those cases signals to the
community that society will enforce social norms, but will
502. See supra Part III (B).
503. Weisberg & Vandervort, supra note 489, at 662; Congdon, supra
note 491, at 644 (providing an example of a model statute).
504. Logli, supra note 320, at 561.
505. Id. at 562.
506. Id. at 563; Johnson, supra note 489, at 49.
507. Johnson, supra note 489, at 49.
508. Id.
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sanction egregious and harmful conduct by setting limits on what
actions are not morally tolerable.509
Finally, states should address the question of how to hold
pregnant and parenting women accountable for actions that
result in harm or death to infants and children. They should
adopt the reasoning proffered by Justice Loughry in the State v.
Louk dissent.510 If a pregnant mother’s drug abuse was a causal
factor in the child’s death or injury, then the law should hold her
criminally accountable. As Logli correctly asserts, ignoring an
infant’s death or evading responsibility by reason of lack of legal
recourse is simply unconscionable.511

CONCLUSION
Prenatal substance abuse moves beyond impacting the
pregnant patient. It influences developmental outcomes for
infants and radiates into the social well-being of families. It also
corresponds to civil interventions and criminal violations for
actions related to substance abuse, such as child neglect, abuse,
and homicide. Women struggling with dependence or addiction
should be offered treatment, assistance, and effective resources to
discontinue substance abuse.
However, health professionals and policymakers must reexamine the unanswered questions of how to address situations
where the treatment itself poses serious risks and consider
whether current clinical recommendations accurately disclose
those risks. This includes situations where the treatment does not
work and pregnant and parenting women continue to abuse
substances while enrolled in treatment or refuse treatment.
Further, policymakers must consider at what point the law can –
and must – intervene to protect infants and children. It is time
to re-assess federal policy and current clinical care standards:
acting as fiduciaries, physicians have an ethical and legal duty to
explain a range of treatment options. During that explanation,
physicians should explain the likelihood of success in
detoxification treatment and the significant physical,

509. Id.
510. State v. Louk, 786 S.E.2d 219, 234-35 (W. Va. 2016).
511. Logli, supra note 320, at 566.
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neurological, and psychological risks of MAT for both the patient
and her future infant.
Currently, pregnant and parenting patients committed to
stopping substance abuse may be advised to adopt MAT without
full disclosure, and as a result, may experience side effects such
as adverse neurological effects, cognitive dysfunction, somnolence,
and impairment. These undisclosed effects render the alreadyexhausting and stressful postpartum period exceedingly difficult
to manage. They may even lead to devastating accidents. Federal
policy, clinical conversations, and state legislation must account
for the high incidence and impact of ongoing substance abuse
even when pregnant and parenting patients are enrolled in
treatment. This requires modifying clinical risk-benefit
calculations and raising the question of what constitutes the best
method of facilitating treatment for pregnant and parenting
women.
Finally, we must not equivocate substance abuse during
pregnancy with a neutral social choice. It exerts a detrimental
impact on infants and children. In the civil context, the law
should provide a mechanism to facilitate treatment for women
with SUD, serve as a lever of accountability, and should motivate
engagement in treatment. Importantly, the law must also
recognize that, in some cases, pregnant and parenting women’s
actions deviate so far from a minimum standard of care that the
state has an affirmative duty to intercede. In doing so, the state
will work to protect the rights of the child, while criminally
sanctioning substance abuse that results in harm or death to
infants and children.

397

